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1. INTRODUCTION 
The skin is the outermost layer of our body serving as the first-line defense 
against environmental factors and pathogens. To maintain this function, various 
cell types in the skin, including keratinocytes, fibroblasts, and innate and adap-
tive immune cells, like dendritic cells, macrophages, mast cells, and T cells, 
need to work and communicate together. Disruption of this balance can lead to 
inflammatory skin diseases, such as atopic dermatitis (AD), psoriasis vulgaris 
(PV), and vitiligo (Gould, 2018; Richmond & Harris, 2014), which are charac-
terized by skin rashes accompanied by itching, redness, and the presence of 
inflammation. These diseases are relatively common among the general popula-
tion and affected people suffer from loss of quality of life, and the accom-
panying socio‐economic costs are high (Lim et al., 2017).  
Inflammatory skin diseases like PV and AD are usually caused by genetic 
predisposition and environmental factors leading to impaired epithelial function 
and altered immunity (Eyerich & Eyerich, 2018). The involvement of keratino-
cytes as major regulators in both the acute and the chronic phase of skin inflam-
mation through cytokine production and surface molecule expression has been 
established (Albanesi et al., 2005). This will lead to an increased immune cell 
infiltration in the skin. The epithelial and immune cells start to produce specific 
cytokines characteristic to a discrete disease. For example, AD is characterized 
by the production of interleukin (IL)-4 that is typical to T helper 2 (Th) or group 
2 innate lymphoid cells (ILC) response in the acute phase, whereas cytokines 
like interferon (IFN)‐γ and IL‐22 are involved in the chronic phase (Weidinger 
& Novak, 2016).  
MicroRNAs (miRNAs) are short ~22 nucleotides (nt) single-stranded non-
coding RNA molecules that together with protein partners regulate gene expres-
sion at the post-transcriptional level (Bartel, 2004; Lau et al., 2001; Lee et al., 
1993). Each miRNA binds through partial complementarity to messenger RNA 
(mRNA) 3’ untranslated region (3’UTR) and thereby functions as a guide 
bringing proteins that initiate the degradation to target mRNA or inhibition of 
Translation. As a single miRNA can target numerous or even hundreds of 
mRNAs (Baek et al., 2008; Selbach et al., 2008), it is thought that more than 
60% of our protein-coding genes are affected by miRNAs (Friedman et al., 
2009).  
Since their discovery, miRNAs have been implicated in many human patho-
logies, including skin diseases. However, there is still relatively little known 
about their functions in association with skin diseases. In this thesis, we investi-
gated the role of hsa-miR-146a-5p, hsa-miR-146b-5p (miR-146a/b) and hsa-
miR-10a-5p (miR-10a). miR-146a and miR-146b belong to the miR-146 family, 
and as they differ only by two nucleotides in the area not binding to mRNA, 
they are thought to target the same set of genes and are mostly known about 
their anti-inflammatory function in various cell types (Paterson & Kriegel, 
2017; Taganov et al., 2006). miR-10a belongs to the miR-10 family and the 
function of miR-10a is often associated with various cancers (Lund, 2010). In 
13 
our studies, we set out to determine the function and regulation of miR-146a/b 
and miR-10a in association with the two most common chronic inflammatory 
skin diseases PV and AD, respectively. We aimed to identify novel direct 
targets of miR-146a/b and miR-10a and how these particular targets and 
miRNAs themselves may influence the development of PV or AD as well as 
inflammation and proliferation of keratinocytes, the processes tightly associated 
with both these diseases.  
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2. LITERATURE REVIEW 
2.1. Skin immunity 
One of the most important functions of the skin is to act as a physical barrier 
and to protect the organism from infections. The outermost layer of the skin, the 
epidermis, is considered to be the primary physical barrier between the orga-
nism and the environment. The epidermis is composed of different cells, of 
which keratinocytes, melanocytes, and Langerhans cells are considered the 
main cell type of the epidermis (Nordlund, 2007). The structure and cellular 
composition of the skin are more precisely described in figure 1. Tight regula-
tion of keratinocyte proliferation is vital to the structure and function of the 
epidermis. Usually, 96% of human basal keratinocytes are in the G0/G1 cell 
cycle phase and are not proliferating due to limited space in the basal layer and 
leading to contact inhibition (Bata-Csorgo et al., 1993; Bauer et al., 1980). 
During differentiation, the basal layer keratinocytes divide and migrate upwards 
forming first the spinous layer, then the granular layer, and in the end the 
cornified layer and eventually shed from the surface (Losquadro, 2017).  
 
 
 
 
Figure 1. Cellular composition of the skin. The epidermis is mostly comprised of 
keratinocytes and has four layers: basal layer, spinous layer, granular layer, and 
cornified layer. The basal layer consists of keratinocytes, melanocytes, and Merkel cells 
and is usually one cell layer thick. Merkel cells are responsible for the light touch 
sensation and melanocytes produce melanin for skin pigmentation. Langerhans cells and 
T cells mediate and control immune responses in the epidermis (Chambers & 
Vukmanovic-Stejic, 2020). The second layer of the skin is the dermis, which is sepa-
rated from the epidermis by the basement membrane. The most abundant cells in the 
dermis are the fibroblasts that produce collagen, elastin, and other proteins (Rippa et al., 
2019). The dermis also protects from pathogens and other toxic substances by immune 
cells, like mast cells, T cells, dendritic cells (DC), and macrophages (Gould, 2018). 
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In the normal healthy epidermis, keratinocytes from the basal layer move to the 
spinous layer in 13 days (Weinstein & Van Scott, 1965). The layers are charac-
terized by specific morphological and biochemical features indicating the state 
of differentiation. For example, keratin 5 (KRT5) and KRT14 are mostly ex-
pressed by basal layer keratinocytes, and the markers of early differentiation 
KRT1 and KRT10 are expressed in the spinous layer (Goleva et al., 2019). 
 
 
2.1.1. The role of keratinocytes in inflammation 
Interestingly, keratinocytes do not only fulfill the role of a structural element, 
but they also participate in the regulation of innate and adaptive immune 
responses (Nestle et al., 2009). First, keratinocytes can have direct protective 
functions as they produce antimicrobial peptides (AMPs) (Clausen & Agner, 
2016). AMPs have antimicrobial activity against bacteria, fungi, and viruses and 
they can modify cell migration, proliferation, differentiation, and cytokine pro-
duction (Clausen & Agner, 2016; Takahashi & Gallo, 2017). Keratinocytes can 
produce different AMPs, like human β-defensin-2 (hBD2), LL-37, psoriasin, 
RNase7, and adrenomedullin, in response to stimuli (Clausen & Agner, 2016). 
For example, IL-12, IL-23, and IL-27 enhance hBD2 secretion and production 
in keratinocytes (Kanda & Watanabe, 2008). 
Secondly, another role of keratinocytes is to transmit signals from the en-
vironment to the immune cells in the skin. As keratinocytes can sense various 
signals through Toll-like receptors (TLR) (Lebre et al., 2007), they can be acti-
vated to produce chemokines and cytokines, which leads to the recruitment and 
activation of various types of immune cells (Miller, 2008; Miller & Modlin, 
2007). In addition, keratinocytes also constitutively or when induced produce 
cytokines like tumor necrosis factor (TNF), members of the IL-1 cytokine fami-
ly, and thymic stromal lymphopoietin (TSLP), (Albanesi et al., 2005; Soumelis 
et al., 2002). Several factors are known to induce the production of TSLP from 
keratinocytes including other cytokines, viruses, bacteria, fungi, and allergens 
(Varricchi et al., 2018). This has a prominent role in promoting Th2 cytokine 
responses in the skin as TSLP-activated DCs promote T cells to differentiate 
into Th2 cells (Soumelis et al., 2002). Additionally, the activation of the inflam-
masome signaling pathway will lead to the production of pro-inflammatory 
cytokines IL-1β and IL-18, members of the IL-1 cytokine family (Martinon et 
al., 2009). Furthermore, keratinocytes express receptors for a broad array of 
cytokines, which makes them sensitive to the inflammatory environment. One 
of the receptors that keratinocytes constitutive express is the IFN-γ receptor 
complex making them sensible to IFN-γ (Albanesi et al., 2005; Barker et al., 
1990).  
Another mode of how keratinocytes help to regulate immune cell trafficking 
is the expression of different chemokines (Figure 2). Resting keratinocytes 
express low levels of IL-8 and c-c motif chemokine ligand 27 (CCL27) mRNA 
(Anttila et al., 1992; Morales et al., 1999). When stimulated, the expression of 
16 
these and other chemokines can be upregulated remarkably. For example, when 
keratinocytes are stimulated with TNF-α or IL-1β, the expression of CCL27 is 
induced (Homey et al., 2000), which attracts a high number of T-cells into the 
skin (Nedoszytko et al., 2014). Some of the other known chemokines produced 
by keratinocytes in response to various stimuli are chemokine (C-X-C motif) 
ligand 1 (CXCL1), CCL20, and CCL5 (Albanesi et al., 2001). IL-8 and CXCL1 
are known for attracting neutrophils, CCL20 mediates the movement of dendri-
tic and Langerhans cells, and CCL5 attracts eosinophils and T-cells (Nedos-
zytko et al., 2014).  
In addition to their capacity to produce proinflammatory cytokines and chemo-
kines, keratinocytes are also capable of producing anti-inflammatory cytokines, 
like transforming growth factor (TGF)-β and IL-10, and receptor inhibitors 
(Stadnyk, 1994). The main functions of IL-10 are to limit inflammation and 
downregulate overwhelming immune response by regulating Th1-Th2 balance, 
inhibiting macrophage and monocyte activation, cytokine production, antigen 
presentation, and T-cell activation (Weiss et al., 2004). Interestingly, keratino-
cytes can produce receptor inhibitors for the IL-1 family IL‐1Ra and IL-36Ra 
(Bigler et al., 1992; Johnston et al., 2011). They bind, respectively, to the same 
receptors as IL-1α and IL-1β, and IL-36α, IL-36β, and IL-36γ, however, pre-
venting the activation of further signaling, including in keratinocytes. Therefore, 
keratinocytes by producing IL‐1Ra and IL-36Ra can modulate the biological 
responses to stimuli that induce respective IL-1 family member expression in 
the cells (Lowes et al., 2013; Sims & Smith, 2010). In summary, keratinocytes 
are an important part of the immunoregulatory network of the skin as they help 
to regulate both immune homeostasis and inflammatory responses. 
 
 
2.1.2. Immune cell functions in the skin 
The skin is rich in different types of immune cells of which some are resident 
cells, and some migrate there in case of infection or inflammation (Figure 2). 
The main immune cell population residing in the epidermis in non-inflamed 
conditions is a specialized subset of tissue-resident macrophages called Lan-
gerhans cells (Doebel et al., 2017; Otsuka et al., 2018), which account for 3–5% 
of epidermal cells (Merad et al., 2008). It has been shown that Langerhans cells 
in mice can promote the Th17 cells by secreting IL-6 in response to pathogens 
such as Candida albicans (Igyarto et al., 2011). However, antigen presentation 
by Langerhans cells can also result in T cell anergy or deletion indicating that 
they have a possible immunoregulatory role and could be involved in peripheral 
tolerance induction (Igyarto & Kaplan, 2013).  
17 
 
Figure 2. Immune cell functions in the skin. Among different immune cells some are 
resident cells and some migrate to the skin in the case of infection or inflammation. 
Each cell subset is characterized by a specific cytokine profile. While Langerhans cells 
reside in the epidermis (Doebel et al., 2017; Otsuka et al., 2018) another subset of 
antigen presenting cells in the skin is dermal DCs (Schraml & Reis e Sousa, 2015; 
Waisman et al., 2017). Even in uninflamed conditions, a diverse types of T helper cells, 
including Th1, Th2, Th17, and Th22 are present in the skin (Raphael et al., 2015). In 
addition, different type ILCs (ILC1, ILC2, and ILC3) that all have specific cytokine 
profiles play a role in barrier immunity (Kobayashi et al., 2020; Vivier et al., 2018). 
Additionally, different types of granulocytes can be recruited, including neutrophils, 
eosinophils, basophils, and mast cells (Bochner & Gleich, 2010; Kita et al., 1991; 
Nauseef & Borregaard, 2014). 
 
 
Another cell type playing an important role in skin immunity is DCs. DCs are 
known as antigen-presenting cells and therefore link innate and adaptive 
immune responses. DC can phagocytose pathogens, and in response, they start 
to produce pro-inflammatory mediators that attract innate immune cells to the 
infection site (Schraml & Reis e Sousa, 2015; Waisman et al., 2017). There are 
different subsets of DC in the dermis, including conventional DC1s and DC2s, 
and, also during inflammation, plasmacytoid DCs, and monocyte-derived DCs 
(Collin & Bigley, 2018; Worbs et al., 2017). Different subsets of DCs have 
specialized functions and can produce specific cytokines and may initiate 
distinct inflammatory responses following activation. For example, conventio-
nal DC2s express a wide range of receptors, such as lectins, TLRs, nucleotide-
binding oligomerization domain‐like receptors and retinoic acid-inducible gene-
I-like receptors (Collin & Bigley, 2018; Kashem et al., 2017) and can activate 
Th1, Th2, Th17, and cluster of differentiation (CD8+) T cells (Di Blasio et al., 
18 
2016; Nizzoli et al., 2016; Sittig et al., 2016). Conventional DC2s, when stimu-
lated, can secrete different cytokines including IL-12, IL‐23, IL‐1, TNF‐α, IL‐8 
and, IL‐10 (Nizzoli et al., 2013; Nizzoli et al., 2016; Sittig et al., 2016). In most 
cases, the DCs participate in the clearance of infectious agents. However, in other 
circumstances, the activation of DCs can lead to pathological tissue responses and 
persistent inflammation. For instance, plasmacytoid DCs have been implicated in 
the pathogenesis of several autoimmune diseases, for example, systemic lupus 
erythematosus, due to their ability to sense self‐nucleic acids and to produce type 
I interferon (Berggren et al., 2015; Lande et al., 2011). 
T lymphocytes play a central role in the immune system as potent effectors 
and regulators of immunity. In the case of noninflamed skin, both CD4+ T cells 
and CD8+ T cells are present in the skin (Klicznik et al., 2018). The T cells are 
divided between different layers of the skin. The majority of T cells are in the 
dermis, most of which are CD4+ T cells in the perivascular area. The epidermis 
contains few T cells, of which the majority are CD8+ tissue-resident memory T 
cells that help to protect the body from infections (Clark et al., 2012). CD8+ T 
cells are also known as killer or cytotoxic T lymphocytes and they also can 
summon circulating memory T cells to the site of virus reactivation or reentry of 
pathogens (Heath & Carbone, 2013). The CD4+ T cell population consists of a 
diverse set of T helper cells, including Th1, Th2, Th17, Th22, regulatory T 
(Treg) cells (Raphael et al., 2015), which all produce characteristic cytokines, 
and have specific roles also in the skin. For instance, Th1 cells secrete IFN-γ 
and protect against intracellular pathogens, such as Mycobacteria and viruses 
(Sallusto, 2016). Th2 cells mediate isotype class-switching to immunoglobulin 
E (IgE) and that contributes to host defense against parasitic worms (Geha et al., 
2003). Th2 cells and the cytokines they secrete (IL-4, IL-5, IL-13, IL-24, IL-25 
and, IL-31) have a central role in various diseases, including AD, asthma, 
chronic rhinosinusitis, and food allergy (Morita et al., 2016). Th17 cells can be 
divided into non-pathogenic and pathogenic Th17 cells. The physiological role 
of the non-pathogenic Th17 cells is to protect against extracellular bacteria and 
fungi by controlling neutrophil migration to the skin. They secrete IL-17A, IL-
17F, IL-10, and, CCL20 (Stadhouders et al., 2018). However, when the Th17 
cells are activated by IL-23 in combination with IL-1β and IL-6, they turn into 
pathogenic Th17 cells that express IL-17A, IL-17F, IL-22, CCL9, and CXCR3 
and are associated with PV, rheumatoid arthritis, multiple sclerosis, and AD 
(Kurebayashi et al., 2013; Yasuda et al., 2019). Additionally, there are distinct 
IL-22–producing CD4+ (Th22) and CD8+ (Tc22) T cells (Nograles et al., 
2009). Th22 cells are defined by the production of IL-22, which together with 
other members of the IL-20 family mediate epidermal hyperplasia and inhibit 
terminal differentiation (Nograles et al., 2009; Sa et al., 2007) as well as 
function in tissue remodeling as they can produce fibroblast growth factor iso-
forms, CCL15 and CCL23 (Eyerich et al., 2009). Treg cells are an immuno-
suppressive subset of T cells, which secrete cytokine IL-10 and thereby relieve 
inflammatory of skin diseases (Honda et al., 2011). 
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ILCs are considered as the innate counterpart of adaptive T cells and they 
can be activated by alarmins, cytokines, and other inflammatory mediators 
expressed by tissue-resident cells enabling rapid responses to environmental 
signals (Kobayashi et al., 2020; Vivier et al., 2018). The ILCs have three groups 
based on the expression of key transcription factors. Group 1 ILCs comprise 
natural killer (NK) cells and ILC1s and express the transcription factor T-bet 
and they are able to produce IFN-γ, granzymes, and perforins. They mediate 
type 1 immunity and can react to intracellular microorganisms such as viruses 
and bacteria (Kobayashi et al., 2020). Group 2 ILCs are ILC2s and they express 
the transcription factors GATA Binding Protein 3, RAR-related orphan receptor 
(ROR) alpha, and MYC proto-oncogene (C-MYC). They produce IL-4, IL-5, 
IL-9, and IL-13 in response to parasites and allergens and participate in type 2 
immunity (Akdis et al., 2020). Additionally, ILC2s have been shown to be 
upregulated in AD skin and contribute to the increase in type 2 cytokine 
production in the skin (Salimi et al., 2013). Group 3 ILCs comprise lymphoid 
tissue-inducer cells and ILC3s and their development are dependent on the 
expression of RORγt and they produce IL-17, IL-22, and TNF which they pro-
duce in response to extracellular bacteria and fungi (Polese et al., 2020). In the 
case of PV, it has been shown that there is an increase of ILC3s in the lesional 
skin of PV patients contributing to the development and maintenance of PV 
(Dyring-Andersen et al., 2014; Teunissen et al., 2014). 
In response to the activation of tissue-resident immune cells and keratino-
cytes and their subsequent release of chemokines, different types of granu-
locytes, including neutrophils, eosinophils, basophils, and mast cells are re-
cruited to the skin. Neutrophils are the first cell type to be recruited to the skin 
after the activation of antigen-presenting cells in response to infection (Nauseef 
& Borregaard, 2014). Neutrophils can efficiently phagocytose pathogens, 
degrade them by synthesizing reactive oxygen species inside phagolysosomes, 
kill pathogens by degranulation of AMPs, or create extracellular traps to trap 
pathogens (Bardoel et al., 2014). Eosinophils participate in antiparasitic and 
allergic responses. The activation of eosinophils leads to the secretion of IL-5, 
IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
degranulation of cationic toxins that help to kill microbes and parasites 
(Bochner & Gleich, 2010; Kita et al., 1991). Eosinophils also participate in 
inflammatory responses, which may lead to tissue damage, fibrosis, and the 
development of hypercoagulability (Rosenberg et al., 2013). As a result, eosino-
phils are important in different eosinophilic dermatosis and many allergy-
related diseases including allergic drug eruption, urticaria, allergic contact 
dermatitis, and AD (Heymann, 2006). Mast cells can secrete mediators that 
regulate eosinophil activation and recruitment including IL-5, IL-6, TNF-α, 
GM-CSF, tryptase, eotaxins, CCL5 (Shakoory et al., 2004). Both eosinophils 
and mast cells are associated with Th2 responses, and therefore, they also play a 
role in allergic diseases, including allergic contact dermatitis, AD, allergic rhini-
tis, and bronchial asthma (Ito et al., 2011; Kawakami et al., 2009).  
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2.1.3. Pro-inflammatory signaling pathways  
In the case of inflammation, pro-inflammatory signaling pathways are activated 
in the different types of cells in the skin, including keratinocytes. Among the 
key signaling pathways activated during inflammation is the nuclear factor 
kappa B (NF-κB) and the Janus Kinase (JAK)/Signal Transducer and Activator 
of Transcription (STAT) pathways (Shi et al., 2017; Villarino et al., 2017). The 
activation of both pathways is described in figure 3. The NF-κB signaling 
pathway can be activated by many stimulatory molecules, like TNF-α, IL-17, or 
infections by various pathogens (Osborn et al., 1989; Pahl, 1999; Shalom-Barak 
et al., 1998). The NF-κB transcription factor can induce the expression of hund-
reds of target genes (Zhang et al., 2017), many of them are related to the host 
immune response, including cytokines or chemokines like CCL5, IL-1α, and IL-
8, or regulation of apoptosis or cell growth (Kunsch & Rosen, 1993; Mori & 
Prager, 1996; Pahl, 1999). 
Another signaling pathway commonly activated in inflammatory skin disea-
ses is the JAK/STAT pathway. Over 60 cytokines and growth factors use the 
JAK/STAT pathway for their signaling (Howell et al., 2019). For example cyto-
kines like IL‐19, IL‐20, IL‐22 and, IL‐23, which are also highly expressed in 
psoriatic lesions, signal through the JAK/STAT pathway (Dumoutier et al., 
2001; Witte et al., 2014). There are four Janus kinases (JAK1, JAK2, JAK3, and 
tyrosine kinase 2 (TYK2)) and seven STATs (STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, STAT6). In mammals JAK1, JAK2, and TYK2 are 
expressed everywhere. However, JAK3 expression is specific to hematopoietic 
and lymphoid tissues (Ghoreschi et al., 2009). The activation of STAT induced 
gene expression will lead to different effector responses. For example, STAT1 
and STAT4 activate the antiviral Th1 type response and STAT3 regulates the 
anti‐bacterial/fungal Th17 type response (Welsch et al., 2017). Cytokines can 
activate different STAT proteins at the same level or one of the STATs more 
strongly. For instance, INF-γ activates both STAT1 and STAT3, however, the 
STAT3 response is much weaker (Qing & Stark, 2004). Also, one STAT 
protein can be activated by different cytokines. For example, IL‐6, IL‐10, IL‐21, 
IL‐22, and IL‐23 all signal through STAT3 (Hirahara et al., 2015; Yang et al., 
2011).  
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Figure 3. NF-κB and JAK/STAT signaling pathways. Activation of the NF-κB and 
JAK/STAT signaling pathways occurs through different types of receptors, including 
the interferon-gamma receptor (IFNGR), TLR, and G protein-coupled receptors 
(GPCR) by various stimuli. In case of signaling through TLRs, a cascade of protein 
phosphorylation-associated events leads to the association of MyD88 with TLR intra-
cellular part, recruitment of interleukin-1 receptor-associated kinase 4 (IRAK4), 
IRAK1, and TNF receptor-associated factor 6 (TRAF6) (Akira & Takeda, 2004; Cao et 
al., 1996). The phosphorylated IRAK1 and TRAF6 detach from the receptor, this even-
tually leads to the phosphorylation of mitogen-activated protein (MAP) kinases and the 
IκB kinase (IKK) complex, which will result in phosphorylation of the NF-kappa-B 
inhibitor alpha (IκBα) that will be ubiquitylated and therefore degraded enabling the 
NF-κB dimer to be imported to the nucleus where it activates the expression of its target 
genes (Akira & Takeda, 2004; Gilmore & Herscovitch, 2006). If the stimulatory signal 
comes from GPCR, the caspase recruitment domain-containing protein 10 (CARD10) 
forms a complex with mucosa-associated lymphoid tissue lymphoma translocation pro-
tein 1 (MALT1), which leads to the phosphorylation of IKK, degradation of the 
complex and activation of NF-κB (Grabiner et al., 2007; Mahanivong et al., 2008). The 
activation of the JAK/STAT signaling pathways is initiated by binding of cytokine or 
growth factor to the corresponding transmembrane receptor, leading to the phospho-
rylation and activation of the JAKs. The activated JAKs then phosphorylate STAT 
monomers, which dimerize and translocate to the nucleus where they directly engage 
DNA regulatory elements to activate the transcription (Howell et al., 2019; Villarino et 
al., 2015). Different steps of the JAK/STAT pathway are tightly regulated, for example 
by suppressor of cytokine signaling (SOCS) family of proteins that act as negative 
regulators (Villarino et al., 2015). 
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The interplay between epidermal keratinocytes, stromal, and immune cells 
results in an effective host defense against various pathogens and maintains or 
restores skin homeostasis. Some immune cells, like skin-resident memory T 
cells, have the capacity to migrate into the skin, terminally differentiate and 
reside there and thereby maintain memory to protect against future reinvasion 
(Mueller et al., 2014). However, in the case of PV, it has been shown that 
CD49a– skin-resident memory T cells are responsible for the augmented IL-17 
production (Cheuk et al., 2017). Other cells are rapidly recruited to the skin in 
case of infection. For example, neutrophils are considered as one of the first cell 
types to be recruited to the inflammation site after injury (Kovtun et al., 2018). 
Altered communication or dysregulation of these cell types can lead to chronic 
inflammatory skin diseases or other conditions like, inflammatory bowel di-
sease and hematologic malignancies (Baumgart & Carding, 2007; Bachireddy et 
al., 2015). For example, in the case of psoriasis, the increased number of neutro-
phils contributes to the development and progression of the disease (Chiang et 
al., 2019). Chronic infections in case of inadequate skin immunity is also often 
associated with various pathogens, such as Candida albicans or Staphylococcus 
aureus (Giardino et al., 2016).  
 
 
2.2. Chronic inflammatory skin diseases 
2.2.1. Psoriasis vulgaris 
Psoriasis is a common inflammatory skin disease with a prevalence of approxi-
mately 2–3 % in Europe and the United States (Parisi et al., 2013). It has two 
main forms PV and pustular psoriasis. The most common form of psoriasis, PV, 
also known as plaque psoriasis, representing almost 90% of psoriatic patients 
(Boehncke & Schon, 2015). There are two peak ages of onset, early-onset 
between 15 and 30 years, and late-onset 50 and 60 years (Boehncke & Schon, 
2015). PV is characterized by often symmetrical monomorphic and demarcated 
erythematous plaques with white scaling that appear mostly on the scalp, trunk, 
and extensor surfaces. However, in some cases, it can lead to erythroderma 
affecting the entire body surface (Boehncke & Schon, 2015). Histologically, 
psoriatic skin lesions are characterized by acanthosis, the thickening of the epi-
dermis, leukocyte infiltrates, and an increased number of tortuous and leaky 
vessels in the dermis (Griffiths & Barker, 2007) (Figure 4). PV is not only a 
skin disease: it is associated with comorbidities, such as psoriatic arthritis, 
cardiovascular disease, metabolic syndrome (obesity, hypertension, dyslipi-
demia, and diabetes), chronic kidney disease, gastrointestinal disease, mood dis-
order, malignancy, and systemic inflammation that increases the risk for death 
(Gelfand et al., 2007; Takeshita et al., 2017a, 2017b).  
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Figure 4. Cellular composition of psoriatic skin. The thickening of the epidermis or 
epidermal hyperplasia in psoriatic lesions is caused by increased keratinocyte prolife-
ration, which may lead up to an eightfold increase in epidermal cell turnover (Bata-
Csorgo et al., 1993). The increased transition of keratinocyte to the upper layers leads to 
altered protein expression, loss of a mature granular layer, and retention of keratinocyte 
nuclei (parakeratosis). There is an increased influx of inflammatory cells into the skin, 
including inflammatory DCs, neutrophils, effector Th1, Th17, and Th22 (Boehncke & 
Schon, 2015) that further drive the inflammation.  
 
 
PV has a strong genetic background that is illustrated by the evidence that up to 
70% of monozygotic twins and 20% of dizygotic twins share the disease 
(Farber et al., 1974; Griffiths & Barker, 2007). Also, epidemiologic studies 
have shown a higher prevalence of PV among the relatives of patients as com-
pared to the general population (Boehncke & Schon, 2015). To date, genome-
wide linkage studies have identified at least 60 chromosomal loci linked to 
psoriatic susceptibility (Elder, 2018). The PSORS1 locus, which is a 220-kb 
region found on chromosome 6p21.3, has been shown to contribute between 
35% and 50% of the heritability of psoriasis and has the largest effect size (Nair 
et al., 1997; Trembath et al., 1997; Veal et al., 2002). One of the alleles in 
psoriasis susceptibility 1 (PSORS1) region is the human leukocyte antigen C 
(HLA-Cw6 (C*06:02)), which encodes a class I major histocompatibility 
complex molecule that is expressed on antigen-presenting cells and involved in 
CD8+ T-cell activation and it is present in more than 60% of patients and 
increases the risk for PV over 9–23 times (Gudjonsson et al., 2003). The 
presence of HLA-Cw6 is more likely to be associated with early onset PV (Nair 
et al., 2006). In addition, many linked loci include candidate genes that are 
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related to immune pathways like antigen presentation, innate antiviral signaling, 
and Th17 cell activation (Tsoi et al., 2015). For example, many of the genes 
linked with PV are related to cytokine and cytokine receptors and their 
signaling, including IL23A, IL12B, IL23R, TYK2 and STAT3 (Tsoi et al., 2012). 
Another gene associated with PV and involved in NF-κB signaling is CARD14, 
which is highly expressed in keratinocytes (Scudiero et al., 2011; Tsoi et al., 
2012). Mutations in CARD14 have been shown to cause constitutive NF-κB 
activation, leading to enhanced production of pro-inflammatory cytokines and 
increased risk of PV (Berki et al., 2015; Sugiura et al., 2014).  
 
 
2.2.1.1. Pathophysiology of PV  
Psoriatic lesions usually develop in the same skin areas susceptible to frequent 
friction or minor trauma, known as Koebner’s phenomenon (Weiss et al., 2002). 
The development of psoriatic lesion usually starts with immune activation 
following environmental stimuli, including exogenous trauma, infections or 
drugs (Di Meglio et al., 2014) and the loss of immune tolerance to psoriasis 
autoantigens, like LL37, a disintegrin-like and metalloprotease domain-con-
taining thrombospondin type 1 motif-like 5 (ADAMTSL5), and phospholipase 
A2 group IVD (PLA2G4D)-generated neolipids (Arakawa et al., 2015; Cheung 
et al., 2016; Lande et al., 2014). Activated Th17 cells in the skin produce 
several cytokines, including IL-17A, IL-17F, TNF-α, and IL-22 (Blauvelt & 
Chiricozzi, 2018). IL-17A is considered as one of the major effector cytokines 
in PV, which can act synergistically with TNF-α to induce the expression and 
release of many psoriasis-related proteins from keratinocytes, including hBD2, 
lipocalin 2, S100 proteins, and LL37 (Wang et al., 2013). Th1 cells contribute 
to the increase of IFN‐γ, TNF‐α, and IL-12 in psoriatic lesions (Austin et al., 
1999). TNF‐α activates the NF‐κB pathway that affects lymphocyte and 
keratinocyte survival, proliferation, and apoptosis (Ogawa et al., 2018). On the 
other hand, IL-22 produced by Th22 cells has been shown to cause epidermal 
hyperplasia, hypogranulosis, and parakeratosis. These processes are all as-
sociated with disruption of normal terminal differentiation of keratinocytes in in 
vitro reconstituted human epidermis, indicating that IL-22 is one of the cyto-
kines contributing to acanthosis and parakeratosis in PV (Boniface et al., 2005; 
Sa et al., 2007; Wolk et al., 2009). Figure 5 describes the proposed mechanisms 
leading to loss of immune tolerance to psoriasis autoantigen LL37. 
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Figure 5. Pathophysiology of PV. The loss of immune tolerance to psoriasis auto-
antigen LL37 in complex with DNA will lead to the activation of plasmacytoid DCs 
(Morizane et al., 2012). The activated plasmacytoid DCs and damaged keratinocytes 
start to produce type I IFN (IFN-α and IFN-β) and TNF-α, which results in further 
production of TNF-α, IL-12 and IL-23 by plasmacytoid and recruited inflammatory 
DCs (Lande et al., 2007; Lowes et al., 2014). From the produced cytokines, IL-12 
promotes the differentiation of naïve CD4+ T cells into IFN-γ-producing Th1 cells. 
The cytokine IL-23 drives the polarization, clonal expansion, and activation of Th17 or 
Th22 cells, which leads to the production of IL-17 and IL-22 (Hawkes et al., 2018; 
Langrish et al., 2005; Lowes et al., 2014). Additionally, Th17 cells produce TNF-α, 
IL-26, and IL-29 that activate keratinocytes, which start to produce chemokines 
CXCL9, CXCL10, and CXCL11, which in turn recruit more Th1 cells (Stephen-
Victor et al., 2016; Wolk et al., 2013). IL-17A is also known to upregulate the expres-
sion of TNF-α (Blauvelt & Chiricozzi, 2018) CXCL1, CXCL2, and IL-8 in keratino-
cytes, which attract neutrophils (Reich et al., 2015). 
 
In the case of psoriasis, neutrophils secrete a variety of proinflammatory sig-
nals, including reactive oxygen species, IL-17, and neutrophil extracellular traps 
(Lin et al., 2011). Neutrophils also have a role in amplifying the IL-36 driven 
inflammatory processes in PV. The released extracellular traps contain several 
proteases including elastase (SERPINA1) and cathepsin G (SERPINA3), that 
are required for the cleavage of IL-36α, IL-36β and IL-36γ to their truncated 
and more biologically active forms (Clancy et al., 2017; Henry et al., 2016; 
Towne et al., 2011). IL-36α, IL-36β, and IL-36γ are highly expressed in 
psoriatic skin (Johnston et al., 2011; Keermann et al., 2015) and they, in turn, 
activate keratinocytes (Carrier et al., 2011). Also, IL-36 can stimulate the 
maturation and function of antigen-presenting cells. For example, monocytes 
and myeloid DCs both secrete more IL-1β and IL-6 when the cells were 
stimulated with IL-36 family members (Foster et al., 2014). 
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2.2.1.2. Therapy 
PV is a chronic disease that usually requires long-term therapy. Most often, 
Psoriasis Area and Severity Index (PASI) is used to help quantify disease 
severity as PASI takes into consideration the affected body surface area along 
with redness, scaling, and cellular infiltration. PV is considered mild when the 
PASI values are <10, moderate at 10–20 and severe >20 (Spuls et al., 2010). 
The disease severity and other comorbidities will determine the most suited 
choice of therapy (Mrowietz et al., 2011). For the case of mild to moderate PV, 
it is often treated topically using a variation of vitamin D analogs, narrow-
band phototherapy, and glucocorticoids. Traditionally moderate to severe PV 
have been treated with systemic treatment like methotrexate, cyclosporin A, 
and retinoids (Rendon & Schakel, 2019). In recent years, the treatment has 
shifted more towards the use of systemic therapies that target specific inflam-
matory pathways by using complex engineered molecules including mono-
clonal antibodies and receptor fusion proteins (Rendon & Schakel, 2019). The 
longest-used biologicals are those that inhibit TNF-α by binding to its soluble 
and membrane-bound form. Currently, three TNF-α inhibitors are used in the 
treatment of psoriatic disease. These include infliximab and adalimumab 
which are monoclonal antibodies and etanercept that is a fusion protein of the 
TNF receptor to the constant end of the IgG1 antibody (Campanati et al., 
2019). Understanding the role of IL-23 in shaping the Th17 response in PV 
has led to the development of antibodies against IL-17A (secukinumab, 
ixekizumab, and brodalumab) (DʼAdamio et al., 2019; Langley et al., 2014; 
Mease et al., 2017) and IL-23 (ustekinumab, guselkumab, tildrakizumab, 
risankizumab) (Famenini & Wu, 2013; Papp et al., 2017a; Reich et al., 2017), 
which are now all used in the treatment of PV. 
 
 
2.2.2. Atopic dermatitis 
AD is characterized by acute flare‐ups and exacerbations, generalized skin 
dryness, recurrent eczematous lesions on dry skin accompanied by intensive 
pruritus. There are also a set of stigmata that are associated with AD, including 
Dennie–Morgan lines, hyperlinearity of the palms and soles, and Herthogeʼs 
sign (Weidinger & Novak, 2016). The cellular composition and histology of AD 
are shown in figure 6. The disease prevalence is up to 20% in children and 
about 2–5 % of the adult population in developed countries (Akdis et al., 2006; 
Barbarot et al., 2018). AD onset can be during early infancy and childhood but 
can persist or start in adulthood (Weidinger & Novak, 2016). The skin lesions 
mostly occur on flexural sites and in rare cases can generalize to secondary 
erythroderma (Weidinger & Novak, 2016). The skin of AD patients has an 
overall decrease in microbial diversity (Tauber et al., 2016) and is highly 
susceptible to complicating infections with Staphylococci and Herpesviridae 
(Weidinger & Novak, 2016). The loss of this diversity leading to S. aureus 
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dominance may occur shortly before AD flares (Kong et al., 2012). The 
increased levels of S. aureus in the epidermis correlates with increased IL-4, IL-
13, IL-22, and TSLP and decreased expression of AMPs (Nakatsuji et al., 
2016). The quality of life of AD patients is impaired especially in case of 
extensive lesions and itch (Holm et al., 2016). Several systemic comorbidities 
are associated with AD, including obesity, mental problems, and autoimmune 
diseases (Brunner et al., 2017). Also, AD-like food allergy in infants may 
progress to other atopic disorders, including asthma and allergic rhinitis in 
later childhood or adulthood (Schneider et al., 2016; Thomsen, 2015). 
 
 
 
Figure 6. Cellular composition of AD skin. The acute lesions histologically are 
characterized by epidermal intercellular edema, thickening of the stratum corneum, and 
parakeratosis. Additionally, chronic lesions are characterized by diffuse epidermal 
hyperplasia (Kawakami et al., 2009). There are more inflammatory cells recruited to the 
skin, including inflammatory DCs, eosinophils, mast cells, and effector Th2 and Th22 
(Weidinger & Novak, 2016).  
 
 
AD is considered as a multifactorial and heterogeneous disease characterized by 
different clinical phenotypes based on interactions of susceptibility genes, 
impaired skin barrier integrity, and immune dysregulation (Weidinger & Novak, 
2016). One of the defining factors in AD is a defective barrier function that is 
considered fundamental in its pathogenesis. It has been shown that epidermal 
expression of barrier function-related proteins, such as filaggrin (FLG), loricrin, 
and involucrin are decreased. The impaired epidermal barrier allows the interaction 
of skin DCs with different irritants, pathogens, and allergens (Czarnowicki et al., 
2017). Consequently, the onset of AD is also affected by different environmental 
factors. For example, over 85% of AD patients are IgE sensitized to house dust mite 
and this may play a role in acute flare‐ups (DʼAuria et al., 2016).  
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Pruritus is one of the main symptoms of AD, the itch-scratch cycle induces 
further inflammation through the release of TSLP, IL-13, and IL-31 that stimu-
late nerve fibers and upregulate cellular pruritogens. The interplay between 
keratinocytes and immune cells is important in itch regulation because these 
cells generate mediators that contribute to the sprouting of nerve fibers and 
stimulate sensory nerve endings (Weidinger & Novak, 2016). IL-31 produced 
by Th2 cells has been shown to induce severe itching and dermatitis in trans-
genic mice and also in patients with AD (Cheung et al., 2010; Dillon et al., 
2004; Takaoka et al., 2006). IL-31 induces a specific transcriptional profile in 
sensory neurons that causes nerve elongation and branching leading to increased 
sensitivity and sustained itch (Feld et al., 2016).  
Genetically, AD is associated with at least 31 significant susceptibility loci, 
which have been linked to genes involved in skin barrier function, keratinocyte 
differentiation, innate and adaptive immune responses and cytokines, and 
chemokines (Paternoster et al., 2015). The strongest link with AD has 
the FLG gene, encoding the epidermal structural protein FLG that has a role in 
skin barrier function, keratinocyte differentiation, and epidermal homeostasis 
(Palmer et al., 2006). FLG deficiency is associated with early-onset, severe AD, 
greater allergen sensitization, and increased susceptibility to infections (Sze-
gedi, 2015). However, even if FLG gene is associated with AD, the mutations in 
the FLG gene are found only in 15% to 50% of the patients, and 40% of FLG 
mutation carriers never develop AD (Palmer et al., 2006). Therefore, factors 
other than FLG gene play a role in the development of AD. For example, genes 
encoding other structural and tight junction proteins may have influence. Con-
cordantly, reduced expression of Claudin-1 in the epidermis of AD patients 
inversely correlates with both total IgE levels and eosinophil numbers (De 
Benedetto et al., 2011). In addition, variations in genes encoding serine pro-
teases and inhibitors have also been associated with AD as they play a role in 
epidermal barrier homeostasis, including regulation of stratum corneum desqua-
mation, lipid barrier construction and cornified cell envelope (Werfel et al., 
2016a). For example, the serine protease inhibitor Kazal-type 5 that is known to 
regulate proteolysis, keratinocyte differentiation, and maintenance of the normal 
skin barrier is associated with the incidence of AD in the Japanese population 
(Kato et al., 2003). Many other genes associated with AD are related to innate 
and adaptive immune responses, of which some are related to the Th2 type 
cytokines (IL-4/IL13) or IL-1 family receptors (IL1RL1/IL18R1/IL18RAP) (Ta-
mari & Hirota, 2014). It has been also shown that JAK/STAT pathway‐related 
loci have been associated with risk for AD, including polymorphisms within the 
IL6R, IL2/IL21, IL7R, IL15RA/IL2RA and STAT3 genes (Paternoster et al., 
2015).  
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2.2.2.1. Pathophysiology of AD 
AD is a complex disease that involves both innate and adaptive immune co-
unterparts of the immune system in its pathogenesis. The major cell types in-
volved are keratinocytes, Th2 cells, ILC2s, Th22 cells, DCs, eosinophils, and 
mast cells, however, in particular patient groups also Th17, Th1 and cytotoxic T 
cells have influence (Czarnowicki et al., 2019; Malik et al., 2017). DCs are 
considered as one of the most important cell types, which have been shown after 
allergen challenge to increase the release of pro‐inflammatory cytokines and 
chemokines to initiate Th2 immune responses in the skin of AD patients 
(Hammad et al., 2010; Novak, 2012). The Th2 cell type reactions involve 
ILC2s, eosinophils, mast cells, and itch‐promoting cytokines like IL‐31 and IL-
4 (Werfel et al., 2016a). The Th2 type cytokines promote mast cell and eosino-
phil differentiation and antibody responses, including IgE isotype-switching 
(Gittler et al., 2012). The first events during initiation of AD may have different 
mechanistic routes. One scenario is depicted in figure 7. 
 
 
 
Figure 7. Pathophysiology of AD. As a result of physical injury, microbial products, 
or inflammatory cytokines, keratinocytes start to produce TSLP that activates inflam-
matory DCs that in turn induce the development of Th2 cells that express IL-4, IL-5, 
and IL-13. The Th2 type cytokines promote mast cell and eosinophil differentiation 
(Guttman-Yassky et al., 2011). Additionally, TSLP stimulates DCs to produce various 
inflammatory mediators including CCL24, CCL22, and CCL17 (Liu, 2007) and mast cells 
to produce IL-5, IL-6, IL-13 (Allakhverdi et al., 2007). Alternatively, the impairment of 
the skin barrier causes keratinocytes to produce IL-25, IL-33, and TSLP that in turn affect 
dermal group ILC2 cells to produce IL-5, IL-9, and IL-13 (Wang & Beck, 2016). This will 
activate the Th2 cells and the production of Th2 cytokines like IL‐4, IL‐13, and IL‐33, 
which damage the skin barrier even further. Langerhans cells have been shown to induce 
both Th2 and Th22 cells (Fujita et al., 2009; Klechevsky et al., 2008). 
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It has been shown that IL-4 and IL-13 reduce FLG expression of human 
keratinocytes in vitro (Howell et al., 2009). Th2-associated cytokines also 
inhibit other barrier-related genes, such as loricrin and involucrin (Kim et al., 
2008), the production of AMPs, like LL-37 and hBD2 (Clausen & Agner, 2016; 
DʼAuria et al., 2016) leading to the increased infection of the skin of AD pa-
tients (Williams & Gallo, 2015). The effect of IL-9 is seen on T-cells, where it 
drives T-cell survival, proliferation, and secretion of inflammatory mediators 
(Clark & Schlapbach, 2017). Additionally, IL-9 affects also keratinocytes, 
where it induces the expression of vascular endothelial growth factor, which can 
be associated with epidermal changes (Ma et al., 2014).  
Both Th22 and Tc22 cells have been shown to play an important role in the 
pathophysiology of AD, they produce IL-22 that is upregulated in lesional skin 
of chronic AD and the number of CD8+ T cells producing IL-22 correlated with 
the disease activity score of AD (Nograles et al., 2009). Also, it has been shown 
that serum IL-22 levels positively correlated with serum levels of CCL17, a 
marker of AD severity (Hayashida et al., 2011). The chemokine CCL17 is con-
sidered to have a causative role in the accumulation of Th2 cells into lesional 
skin as its receptor CCR4 is mainly expressed on Th2 cells (Kakinuma et al., 
2001). Studies with in vitro cultured human keratinocytes have shown that IL-
22 is capable of downregulating the expression of FLG, loricrin, and involucrin 
in keratinocytes thereby contributing to the decreased barrier function as well 
(Boniface et al., 2005; Gutowska-Owsiak et al., 2011; Nograles et al., 2008). 
During the onset of the lesion Langerhans cells have been shown to also induce 
both Th2 and Th22/Tc22 cells (Fujita et al., 2009; Klechevsky et al., 2008).  
Mast cells and eosinophils are both implicated in the development of AD 
and their numbers are increased in patients with AD (Kawakami et al., 2009; 
Simon et al., 2004). Mast cells contribute to the development of AD as they can 
express IL-22 (Mashiko et al., 2015) and might contribute to the IgE-mediated 
inflammation and eosinophil influx to tissues (Williams & Galli, 2000). Mast 
cells produce histamine and other inflammatory mediators that contribute to 
itching and inflammation in patients with AD (Kawakami et al., 2009). The role 
of histamine is mainly associated with erythema and edema in patients with AD 
(Kawakami et al., 2009). In the tissue, eosinophils can produce IL-4 and pro-
mote inflammation by the production of cationic granules, such as eosinophil 
peroxidase (Chu et al., 2014). The survival and mobilization of eosinophils are 
affected by the levels of Th2 cytokine IL-5, which is increased in the serum of 
patients with AD and also correlates with disease activity (Kondo et al., 2001). 
 
 
2.2.2.2. Therapy 
AD is a complex disease with many different features in its pathophysiology, 
therefore, the treatment of AD is relatively more complicated. In addition to 
conventional treatment of the disease, the patients are instructed to avoid factors 
that might irritate the skin, including environmental irritants and different 
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allergens as they may induce or exacerbate skin lesions (Plotz & Ring, 2010). 
The basic AD therapy includes treatment with topical agents that restore barrier 
function, like the use of different emollients, lipid-based barrier repair formu-
lations. The endpoints are to hydrate the skin, prevent transepidermal water loss, 
and suppress pruritus (Fleischer & Boguniewicz, 2010). Also, agents that have 
anti-inflammatory effects and suppress the immune responses are used in the 
treatment. The use of topical corticosteroids and calcineurin inhibitors pimecro-
limus and tacrolimus are the first-line therapy to treat areas of visible disease 
(Fleischer & Boguniewicz, 2010; Ruzicka et al., 1997). In addition, systemic 
immunosuppressive therapies, including systemic corticosteroids, cyclosporin 
A, and methotrexate are used to stop an acute exacerbation or in patients with 
aggressive AD (BuBmann et al., 2009; Darsow et al., 2010). To relieve the 
pruritus, antihistamines are used as an add-on therapy to other topical or 
systemic approaches (Sidbury & Hanifin, 2000). In line with the importance of 
Th2 responses in AD, the clinical efficacy of dupilumab has been demonstrated 
in adult and adolescent patients suffering moderate-to-severe AD (Beck et al., 
2014; Renert-Yuval & Guttman-Yassky, 2020). Dupilumab is a human mono-
clonal antibody targeting the IL-4 receptor α (IL-4Rα) and thereby inhibits both 
IL-4 and IL-13 signaling. Dupilumab improves the symptoms of AD, pruritus, 
anxiety, and depression, and quality of life (Simpson et al., 2016).  
Currently, several other Th2 type cytokine inhibitors are in the development 
for the treatment of AD. For instance, nemolizumab targeting IL-31 is in phase 
II clinical trials and has shown improvements in clinical scores, pruritus, and 
sleep loss (Kabashima et al., 2018). Also, etokimab anti–IL-33 agent is being 
tested for the treatment of AD in a phase IIa clinical study (Renert-Yuval & 
Guttman-Yassky, 2020). As also Th22 cells are implicated in the development 
of AD, the use of antibodies against IL-22 are being tested. For example, 
fezakinumab, the IL-22–blocking monoclonal antibody has shown significant 
clinical improvements in patients with severe AD in a phase IIa clinical study 
(Guttman-Yassky et al., 2018). 
 
 
 2.2.3. Comparison of PV and AD 
When comparing molecular mechanisms of disease pathologies in the skin of 
AD and PV patients, the two diseases are somewhat similar. Both, AD and PV 
lesions have epidermal hyperplasia, alterations in the barrier function and 
keratinocyte differentiation, increased immune cell infiltration, and increased 
expression of proinflammatory cytokines (Guttman-Yassky & Krueger, 2017). 
As epidermal keratinocytes respond to T-cell derived cytokines and change their 
growth and differentiation, the activation of keratinocytes plays an important 
role in lesion development and phenotype in both diseases (Guttman-Yassky & 
Krueger, 2017). AD and PV both have also a strong immune cell component, 
especially in different types of T cells that play a role in the development of the 
diseases (Dainichi et al., 2018). When comparing the types of T cells involved, 
then Th17 cells appear to be dominant in PV (Kim & Krueger, 2017; Papp et 
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al., 2017b) while in the case of AD, Th2 component is always represented and 
plays the most important role in triggering the disease (Guttman-Yassky & 
Krueger, 2017). However, in the chronic phase of AD, the disease is also 
characterized by other types of cytokines (IFN‐γ, IL‐17A, IL‐22, IL‐23, and IL‐
31) that are not related to the Th2 lineage, and also increase in other Th1 related 
chemokines, such as CXCL9, CXCL10 and CXCL11 occur (Gittler et al., 2012; 
Rebane et al., 2012). Interestingly, in different populations, the types of T cells 
involved in the pathogenesis of AD may vary. For instance, in Asian AD in 
addition to Th2 activation, substantial activation of Th17 cells has been 
identified in blood and acute AD skin lesions (Koga et al., 2008) indicating that 
the Asian AD phenotype shares features of both European American AD and 
PV (Noda et al., 2015). Additionally, types of T cells involved in AD change 
with age. It has been shown that in infants the frequency of Th1 is significantly 
lower compared with older patients (Czarnowicki et al., 2020). There are also 
other shared immune cell subsets between the diseases. For example, Th9 cells 
produce IL-9 which is increased both in PV and AD and is known to induce the 
production of inflammatory cytokines from other T cell subsets (Kaplan et al., 
2015; Schlapbach et al., 2014). Additionally, both diseases share a common 
Th22 component (Gittler et al., 2012; Res et al., 2010). Also, myeloid DC that 
secrete IFN-α play a role in lesion formation and also are the largest popu-
lation of dermal DCs in both diseases (Guttman-Yassky et al., 2007; Novak et 
al., 2010). The understanding of molecular pathways in both PV and AD has 
led to the development of different treatment options for the diseases (Campa-
nati et al., 2019; Simpson et al., 2016). Therefore, understanding of both PV 
and AD disease mechanisms might lead to future treatment options. 
 
 
2.3. miRNA biogenesis and function 
Most miRNAs have independent genes (Lagos-Quintana et al., 2001; Lee & 
Ambros, 2001), however, some of the miRNAs originate from introns (Aravin 
et al., 2003; Lagos-Quintana et al., 2003; Lai et al., 2003) or exons of protein-
coding genes (Hsu et al., 2006). miRNA biogenesis is comprised of several 
steps and leads to about ~22 nt long single stranded miRNA loaded to the RISC 
complex, which has capacity to bind mRNA 3’UTR and to initiate the degra-
dation to target mRNA or suppress the translation (Baek et al., 2008; Selbach et 
al., 2008) (Figure 8). miRNAs are considered as fine-tuners of gene expression, 
as the effect of one miRNA on a single gene can be quite modest (Baek et al., 
2008). However, as one mRNA can be regulated by many different miRNAs 
(Bartel, 2009) and when various miRNAs act in a coordinated manner, a strong 
mRNA suppression can take place (Nam et al., 2014). As mentioned in the 
introduction, about 60% of the protein-coding genes are thought to be regulated 
by miRNAs (Friedman et al., 2009). Therefore, most biological processes are 
influenced by miRNAs, including cell proliferation, differentiation, and 
apoptosis (Shenoy & Blelloch, 2014). For example, in the hair follicle bulge 
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cells and basal keratinocytes, miR-125 overexpression increases the prolifera-
tion (Zhang et al., 2011). miRNAs also help to regulate T helper cell differen-
tiation, for instance, miR-19a contributes to Th2 cell development and type 2 
cytokine production (Simpson et al., 2014). As an interesting finding, in some 
cases, miRNAs can increase the expression of their target genes. For example, 
when the RNA induced silencing complex (RISC) complex binds to the target 
mRNA, it can replace repressive RNA binding proteins and therefore increase 
the expression. For example, miR-466l increases the expression of IL-10 in 
macrophages by outcompeting tristetraprolin (Brooks & Blackshear, 2013; Ma 
et al., 2010). As various processes are regulated by miRNAs, their dysregulation 
is associated with many human diseases, including inflammatory skin diseases. 
 
 
Figure 8: miRNA biogenesis and function. miRNA encoding genes are transcribed by 
RNA polymerase II as  primary miRNA (pri-miRNA) transcript with the 5’end cap 
structure and poly(A) tail at 3’ end (Lee et al., 2004). Next, the pri-miRNA is cleaved 
by RNase III enzyme Drosha in complex with two DiGeorge syndrome critical region 
gene 8 (DCGR8) (Denli et al., 2004; Han et al., 2004). As a result, approximately a 60–
65 nt hairpin precursor miRNA (pre-miRNA) is formed (Lee et al., 2003), which then is 
transported to the cytoplasm by Exportin 5 (XPO5) in complex with a GTP-binding 
nuclear protein, RAS-related Nuclear protein GTP (RanGTP) (Bohnsack et al., 2004; 
Lund et al., 2004). In the cytoplasm, the hairpin is recognized by another RNase III 
enzyme, Dicer that cleaves off the loop structure resulting in approximately 22 nt long 
miRNA duplex (Bernstein et al., 2001; MacRae et al., 2007). For the miRNA to be 
functional, it needs to be loaded onto RISC containing the Argonaute (AGO) and 
glycine-tryptophan protein of 182 kDa (GW182) proteins. This is done by heat shock 
cognate protein 70 (Hsc70)/ heat shock protein 90 (Hsp90) chaperones (Iwasaki et al., 
2010). Only one strand of the duplex is used in the RISC complex, while the other 
strand is separated by the N-domain of Ago protein (Diederichs & Haber, 2007;  
Hammond et al., 2000; Kwak & Tomari, 2012). Based on the 6–8 nt long seed 
sequence, which contains minimally nt 2–7 from 5’ end of the miRNA (Bartel, 2009; 
Krol et al., 2010), the RISC complex binds to target mRNA 3′-UTR and causes transla-
tional repression, mRNA deadenylation and decay (Eichhorn et al., 2014; Huntzinger & 
Izaurralde, 2011). The figure is based on information from (Daugaard & Hansen, 2017).  
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Due to their altered expression pattern and capacity to modulate disease-related 
processes, the potential of miRNAs as biomarkers and therapeutic targets are 
intensively investigated. Accordingly, many studies show the dysregulation of 
miRNAs in various diseases, indicating their relevance as biomarkers (Neagu et 
al., 2020). Moreover, miRNAs can be found in body fluids, including urine and 
serum, where their levels reflect the expression of corresponding miRNA in 
blood cells or tissues. For example, in the case of PV, miR-223 and miR-143 
levels in the peripheral blood corresponded to PASI, potentially helping to 
monitor treatment or disease progression (Lovendorf et al., 2014). However, 
although several biomarker platforms are in clinical trials, only a few com-
mercial biomarker platform based miRNAs are available (Bonneau et al., 2019). 
Considering that up or downregulation of miRNAs is associated with disease 
pathogenesis, the modulation of expression miRNAs has been suggested to have 
therapeutic potential. Accordingly, miRNA mimics and inhibitors have reached 
clinical trials. As an example of some of the skin-related therapeutics that are in 
clinical trials is the miR-29b mimic (Remlarsen, MRG-201, miRagen Thera-
peutics) that is in phase I clinical trials for the treatment of scleroderma 
(Gallant-Behm et al., 2019) and the miR-155 inhibitor is in phase I in the 
treatment of cutaneous T cell lymphoma and mycosis fungoides (Cobomarsen, 
MRG-106, miRagen Therapeutics) (Seto et al., 2018). So far, none of the 
miRNA drug candidates have reached phase 3 trials, however, miR-122 repres-
sor (Miravirsen, SPC3649, Roche) against Hepatitis C virus has completed 
phase 2 studies (Hanna et al., 2019). 
 
 
2.4. miRNA functions in keratinocytes and chronic 
inflammatory skin diseases 
The capacity of miRNAs to regulate different processes in the skin and their 
altered expression in various skin diseases have been demonstrated in numerous 
studies (Lovendorf et al., 2015; Singhvi et al., 2018). Accordingly, miRNAs 
have been shown to participate in the regulation of many physiological pro-
cesses in the skin in health and diseases, including barrier function, pigmen-
tation, aging, wound healing, and inflammation (Botchkareva, 2017; Hawkes et 
al., 2016). As maintaining the balance between keratinocyte proliferation, 
migration and differentiation are essential to maintain the structure and function 
of the epidermis, the large number of studies exploring miRNA functions in the 
skin are focused on keratinocytes (Landen et al., 2016) (Figure 9).  
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Figure 9. miRNA functions in keratinocytes. miRNAs can suppress or promote kera-
tinocyte proliferation, migration, differentiation. Additionally, they regulate inflamma-
tory responses and the barrier function of keratinocytes. Based on information from 
(Botchkareva, 2017; Hawkes et al., 2016; Landen et al., 2016). 
 
 
2.4.1. miRNAs role in keratinocyte proliferation  
in association with PV and AD 
An increasing number of miRNAs have been shown to regulate keratinocyte 
proliferation and may affect the development of skin diseases. For example, the 
expression of miR-203, miR-205, miR-31, miR-483-3p, and miR-210 is dys-
regulated in various skin diseases and they all have been shown to modulate 
keratinocyte proliferation through various targets important for the cell cycle 
progression (Singhvi et al., 2018).  
One of the best-characterized miRNAs controlling keratinocyte proliferation 
is miR-203 that is also regarded as one of the central miRNAs in the skin. miR-
203 expression is considered skin-specific, as its expression is more than 100-
fold higher in the skin compared with other organs (Sonkoly et al., 2007). miR-
203 is expressed in the suprabasal layer of the epidermis and is transcriptionally 
activated in the epithelial stem cell progeny upon their asymmetric cell division 
to basal and suprabasal cells (Jackson et al., 2013). There, miR-203 functions in 
the maintenance of basal layer keratinocyte proliferation as it inhibits the 
expression of the transcription factor p63, which is needed for the initiation of 
epithelial stratification (Koster et al., 2004; Lena et al., 2008). miR-203 also 
inhibits other genes important for the control of cell cycle, including S-phase 
kinase-associated protein 2 (Skp2), a cell cycle regulator, and Musashi RNA 
binding protein 2 (Msi2), an RNA-binding protein (Jackson et al., 2013). The 
expression of miR-203 is upregulated in hyper-proliferative keratinocyte 
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pathologies, including PV and chronic venous ulcers (Pastar et al., 2012; Son-
koly et al., 2007).  
miRNAs regulate keratinocyte proliferation also under inflammatory condi-
tions. For example, miR-31 transcription is NF-κB dependent and its expression 
in the cells is upregulated in response to IL-1α, IL-6, IL-17A, TNF-α, IFN-γ, or 
IL-22 (Yan et al., 2015). The target of miR-31 in keratinocytes is protein 
phosphatase 6 (PPP6C), an inhibitor of the G1–S phase transition in the cell 
cycle. When the expression of miR-31 is enhanced, this will lead to miR-31 
mediated increase in basal keratinocyte proliferation leading to epidermal 
hyperplasia. It has been shown that in PV lesional skin, miR-31 expression is 
elevated and ppp6c expression is downregulated (Yan et al., 2015). In contrast 
to miR-31, miR-20a-3p has been shown to suppress the proliferation and 
induced apoptosis of HaCaT cells. Accordingly, in the psoriatic lesions, miR-
20a-3p is downregulated and thereby it can contribute to hyperproliferation and 
aberrant apoptosis of keratinocytes. It has been also shown that IL-22, a 
cytokine known to play a role in both AD and PV pathogenesis can down-
regulate miR-20a-3p in HaCaT cells that are immortalized human keratinocyte 
cell line from adult human skin (Li et al., 2018). These results allow to conclude 
that the inflammatory environment can affect the miRNA levels and this may 
lead to the regulation of the proliferation of keratinocytes and contribute to the 
pathogenesis of skin diseases like AD and PV.  
Besides proliferation, different miRNAs are indicated as positive or negative 
regulators for keratinocyte differentiation. For example, let-7b has been shown 
to promote differentiation of keratinocytes by targeting IL-6 in in vitro and in 
vivo studies (Wu et al., 2018). Interestingly, a recent study identified decreased 
let‐7b‐5p levels in circulating extracellular vesicles as a potential biomarker of 
psoriatic arthritis in patients with PV (Pasquali et al., 2020). Another miRNA, 
miR-23b-3p, which is expressed during the late step of human keratinocyte 
differentiation, was demonstrated to inhibit keratinocyte differentiation by tar-
geting the SMAD transcriptional corepressor TGF-β induced factor homeobox 1 
(TGIF1) and trough this to activate TGF-β signaling (Barbollat-Boutrand et al., 
2017). One more miRNA, miR-143 has been associated with regulating the 
barrier function of the skin. miR-143 is downregulated in the lesional skin of 
AD patients compared to healthy controls (Sonkoly et al., 2010). In human 
epidermal keratinocytes, miR-143 targets IL-13Rα1, thereby regulating the 
effect of IL-13 on epidermal barrier function. As overexpression of miR-143 
blocked the IL-13-induced downregulation of FLG, loricrin, and involucrin in 
keratinocytes (Zeng et al., 2016), indicating that this miRNA may have 
potential in the development of a therapeutic approach for AD. 
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2.4.2. miRNAs in the regulation of inflammatory responses of 
keratinocytes and association with PV and AD 
As keratinocytes play a role in regulating immune responses and transmitting 
signals from the environment to the immune cells, the signals from keratino-
cytes must be tightly regulated. The first data linking miRNAs and inflamma-
tion came from a study in the human monocytic cell line THP-1. When these 
cells were stimulated with lipopolysaccharides (LPS), the upregulation of miR-
146a/b, miR-132, and miR-155 was detected indicating that they may be 
involved in the regulation of inflammatory responses (Taganov et al., 2006). 
The first study concerning miRNAs in the skin inflammation was published by 
Sonkoly et al. in 2007, and it showed that miRNAs are dysregulated in the skin 
of PV and AD patients (Figure 10).  
 
 
 
Figure 10. Examples of miRNAs dysregulated in the skin of PV and AD patients. 
Both diseases have specific miRNA expression profiles in the skin where various 
miRNAs are either upregulated or downregulated. Upregulation is indicated by a red 
and downregulation by a blue arrow. miRNAs changed in both AD and PV are marked 
in green. The figure is based on information from previously published results (Joyce et 
al., 2011; Rebane et al., 2014; Sonkoly et al., 2007).  
 
 
Several dysregulated miRNAs have been shown to contribute to the patho-
genesis of AD. One of the miRNAs downregulated in the chronic lesional skin 
of AD patients is miR-124. miR-124 itself downregulates cytokines IL-8, 
CCL5, and CCL8 in keratinocytes by inhibition of the expression of p65 
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through the direct binding to the 3′UTR of RELA proto-oncogene. Therefore, 
the reduced expression of miR-124 in the skin of AD patients could be respon-
sible for the increased expression of the mentioned chemokines in the skin of 
AD patients (Yang et al., 2017). One of the miRNAs shown to be upregulated in 
AD is miR-155. In the skin, it was shown that miR-155 is mostly expressed in 
the infiltrating immune cells and cytotoxic T lymphocyte-associated antigen 
(CTLA-4) was identified as a direct target of miR-155. CTLA-4 is known as a 
negative regulator of T-cell activation therefore miR-155 decreases CTLA-4 
expression and regulates the proliferation of Th cells (Sonkoly et al., 2010). 
Another direct target of miR-155 is protein kinase inhibitor α (PKIα): inhibition 
of miR-155 resulted in the increased expression of PKIα, tight junction proteins 
occludin and claudin-16, and decreased expression of TSLP HaCaT cells as 
well as in a mouse model of AD (Wang et al., 2019). Consequently, miR-155 
overexpression could contribute to the pathogenesis of AD. 
The cytokines involved in the pathogenesis of AD also regulate the miRNA 
expression in the skin. For example, IL-4 can regulate the expression of miRNAs 
involved in inflammation, angiogenesis, and apoptosis. When keratinocytes were 
stimulated with IL-4, the upregulation of 26 (for example miR‐122‐5p, miR‐
204‐5p, miR‐146b‐5p, miR‐335‐3p, miR‐34b‐3p) and downregulation of one 
miRNA miR‐147a (Bao et al., 2018) was found. The downregulated miR-147a 
function in keratinocytes has not been studied. However, its expression is also 
downregulated in non-small-cell lung cancer where it inhibited the growth and 
metastasis of cells from the non-small-cell lung cancer cell lines H1650 or 
H1299 by targeting CCL5 (DʼAdamio et al., 2019). Therefore, the decreased 
levels of miR-147a in AD could be contributing to the increased levels of CCL5 
in the skin of AD patients. Recently, IL-32 isotype IL-32γ was shown to have 
an inhibitory effect on the development of AD in AD mouse models by 
inhibition of miR-205. The inhibition of miR-205 decreased the expression of 
pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and TSLP in TNF-
α/lFN-γ-treated HaCaT cells through the inactivation of the NF-κB pathway 
(Lee et al., 2020). 
miRNAs with altered expression also contribute to the pathogenesis of PV. 
Among them, miR-31 as one of the most highly overexpressed miRNAs in PV 
skin was shown to target serine/threonine kinase 40 (STK40), a negative regula-
tor of NF-κB signaling. Accordingly, the inhibition of miR-31 in human pri-
mary keratinocytes caused the decreased expression of IL-1β, CXCL1, CXCL5, 
and IL-8 and suppressed the ability of keratinocytes to activate endothelial cells 
and attract leukocytes. Therefore, increased levels of miR-31 in the psoriatic 
skin could increase the inflammation by regulating the production of cytokines 
and leukocyte chemotaxis to the skin (Xu et al., 2013). Another highly over-
expressed miRNA in psoriatic skin is miR-203. Cytokines TNF-α and IL-24 
were identified as direct targets of miR-203, indicating that besides regulation 
of keratinocyte proliferation, miR-203 also controls cytokine signaling by 
repressing key pro-inflammatory cytokines (Primo et al., 2012). The expression 
of miR-203 was also shown to be upregulated by IL-17 in the ears of mice and 
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HaCaT cells (Xu et al., 2017). miR-126 expression is also upregulated in the 
lesional skin of PV patients and its expression positively correlated with PASI. 
The overexpression of miR-126 increased TNF-α, IFN-γ, IL-17A, and IL-22 
expression, while decreased IL-10 expression in HaCaT cells. Also, miR-126 
increased proliferation and decreased the apoptosis rate, hence, contributing to 
the pathogenesis of PV (Feng et al., 2018). Together the studies on miRNA 
functions in cell cultures and skin indicate that restoring the skinʼs normal 
miRNA profile could be one of the therapeutic options in AD and PV. 
 
 
2.5. miR-146 family 
The miR-146 family has two members, miR-146a-5p and miR-146b-5p (miR-
146a/b) that are transcribed by two different genes, MIR146A and MIR146B. 
They are similar in the sequence differing only by two nucleotides in the 3′ part 
of the mature strand outside the seed region. Therefore, miR-146a/b are pre-
dicted to target the same set of genes. In the human genome, the MIR146A gene 
is located within a larger long noncoding RNA host gene, MIR3142HG 
(chromosome 5q33.3), while the MIR146B gene is located in an intergenic 
region of human chromosome 10 (10q24.32) (Taganov et al., 2006). Accor-
dingly, their expression is regulated differently in cells. Both MIR146A and 
MIR146B are reported to be controlled by NF-κB and CCAAT-enhancer-
binding-protein-β (C/EBPβ). However, it should be noted that while miR-146a 
expression is repeatedly shown to be strongly upregulated in response to NF-κB 
activation (Meisgen et al., 2014; Taganov et al., 2006), this seems to be not the 
case for miR-146b, despite its distant promoter region contains a binding site 
for NF-κB2 (Taganov et al., 2006). In addition, MIR146A is regulated by 
transcription factors C-MYC and interferon regulatory factor 3/7 (IRF3/7) while 
MIR146B is regulated by transcription factors Proto-Oncogene C-Fos (c-Fos) 
and STAT3/6 (Paterson & Kriegel, 2017). Based on miRBase data, the mature -
5p strand of both miR-146a and miR-146b is regarded as the bioactive “guide 
strand” and the mature -3p strand as the “passenger strand” (Paterson & Krie-
gel, 2017).  
As mentioned previously, the role of miR-146a/b in the regulation of im-
mune responses was first shown in human monocytes, where miR-146a expres-
sion increased in response to a variety of microbial components and pro-
inflammatory cytokines, like TNF-α and IL-1β. In this study, it was also shown 
that miR-146a/b directly represses the NF-κB signaling cascade members 
IRAK1 and TRAF6 and thereby participate in a negative feedback regulation of 
TLR and cytokine receptor signaling (Taganov et al., 2006). In Treg cells, the 
expression of miR-146a is needed for their suppressor function as it directly 
targets Stat1. As a result, miR-146a prevents the activation of Treg cells and 
their turning into IFNγ-producing Th1-like cells (Lu et al., 2010). In CD4 and 
CD8 T cells, the lack of miR-146a led to hyperresponsiveness after TCR 
stimulation, evident by higher proliferation, prolonged survival, exaggerated 
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activation phenotype, and increased effector cytokine production. These 
changes are due to altered NF-κB activity and changed expression of NF-κB 
responsive genes (Yang et al., 2012). Another study has demonstrated that mice 
lacking miR-146a develop several immune-related phenotypes around the age 
of 6–8 months characterized by splenomegaly, lymphadenopathy, and multi-
organ inflammation and this correlates with the loss of peripheral T cell tole-
rance (Boldin et al., 2011). Additionally, miR-146a can act as a tumor suppres-
sor in the context of the immune system, as mice lacking miR-146a have exces-
sive production of myeloid cells and develop tumors in their secondary 
lymphoid organs (Boldin et al., 2011). Therefore, altering miR-146a expression 
might be a viable treatment option for myeloproliferative and inflammatory 
disorders. Recently it was shown that a miR-146a conjugated to a scavenger 
receptor/Toll-like receptor 9 agonist is a myeloid cell-selective NF-κB inhibitor 
able to target myeloid cells and leukemic cells leading to reduced expression of 
miR-146a targets IRAK1 and TRAF6 (Su et al., 2020). 
The function of miR-146b has been mostly studied in different types of 
cancer. Interestingly, miR-146b can act as both an oncogene and a tumor 
suppressor depending on the type of cancer. The downregulation of miR-146b 
is associated with tumorigenesis and poor outcome in several types of cancer, 
including gliomas, B-cell lymphomas, breast cancer and hepatocellular carci-
noma (Li et al., 2017; Liu et al., 2015; Wu et al., 2014; Xiang et al., 2014). The 
downregulation of miR-146b in breast cancer was associated with NF-κB-
dependent production of IL-6 and subsequent STAT3 activation leading to 
increased migration and invasion of breast cancer cells (Xiang et al., 2014). In 
gliomas, there is an inverse correlation between miR-146b expression and the 
elevation of glioma grades and Ki-67 index and a positive correlation with 
patients’ survival. In glioblastoma cell lines, the overexpression of miR-146b 
significantly reduced proliferation and increased apoptosis (Liu et al., 2015). 
However, in the case of thyroid cancer, miR-146b was shown to be one of the 
most upregulated miRNAs, which plays a role in cancer progression and 
development (Chou et al., 2017; Ramirez-Moya et al., 2018). The over-
expression of miR-146b in thyroid epithelial cell lines led to the hyperactivation 
of phosphoinositide-3-kinase–protein kinase (PI3K)/protein kinase B (AKT) 
signaling, increased proliferation, migration, and invasion, as well as decreased 
apoptosis leading to a more aggressive tumoral phenotype (Ramirez-Moya et 
al., 2018).  
Additionally, miR-146b does participate in the regulation of the immune 
system and immune responses. In human naïve thymic-derived Tregs, miR-
146b is highly expressed compared with naive CD4 T cells. Inhibition of miR-
146b led to enhanced TRAF6 expression and increased NF-κB activation 
causing a reduction in forkhead box P3 (Foxp3) and increased expression of 
anti-apoptotic genes associated with enhanced cell survival, proliferation, and 
suppressive function of Treg cells (Lu et al., 2016). It has been also shown that 
human immunodeficiency virus-1 (HIV-1) infection leads to the upregulation of 
miR-146b in CD4 T cells and CD4 T cell-derived extracellular vesicles, 
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whereas T cell-derived extracellular vesicles overexpressing miR-146b were 
able to transfer miR-146b mimics into endothelial cells and reduce endothelial 
inflammatory responses in vitro and in vivo (Balducci et al., 2019). 
Despite differences in the expression regulation, some of the functions miR-
146a/b have been shown to be overlapping. For example, both miR-146a/b play 
a role in humoral immunity by regulating germinal center reaction. More pre-
cisely, miR-146a controls germinal center responses in B cells by targeting 
multiple CD40 signaling pathway components. Interestingly, loss of only miR-
146a from T cells does not alter humoral responses, however, the deletion of 
both miR-146a/b in T cells was required for the increase in follicular Th cell 
numbers and enhanced germinal center reactions (Utaijaratrasmi et al., 2018). 
Additionally, miR-146a/b both regulate DC apoptosis and cytokine production. 
Overexpression of miR-146a/b increased DC apoptosis and reduced cytokine 
production of IL-12p70, IL-6, and TNF-α. In the same study, it was also shown 
that the decreased levels of miR-146a/b can enhance the ability of DCs to 
activate NK cells producing IFN-γ (Park et al., 2015).  
 
 
2.5.1. miR-146 family function in the skin 
The increased expression of miR-146a/b in both PV and AD lesional skin was 
first shown by microarray analysis already several years ago (Sonkoly et al., 
2007), however, the functions of miR-146a/b in keratinocytes and skin were 
started to be uncovered more recently. An initial study in human primary 
keratinocytes showed that miR-146a expression was upregulated in response to 
TLR2 stimulation in NF-κB and mitogen-activated protein kinase-dependent 
manner. The overexpression of miR-146a suppressed the production of IL-8, 
CCL20, and TNF-α functionally leading to the decreased chemotactic attraction 
of neutrophils by keratinocytes (Meisgen et al., 2014). Simultaneously to the 
study of Meisgen et al. (2014), it was shown that the expression of miR-146a 
can be induced in keratinocytes in response to heat-killed S. aureus, IL-13, IL-
1β, TNF-α, and IL-17A (Rebane et al., 2014). Additionally, overexpression of 
miR-146a in keratinocytes revealed that miR-146a downregulated genes from 
NF-κB signaling, chemokine signaling, and cytokine-cytokine receptor inter-
action pathways. Moreover, in the MC903-dependent mouse model of AD, 
mice lacking miR-146a developed a stronger inflammation compared with WT 
mice, characterized by increased accumulation of infiltrating cells in the dermis, 
elevated expression of IFN-γ, CCL5, CCL8, and Ubiquitin D in the skin of 
miR-146a-/- mice (Rebane et al., 2014). Although mice lacking miR-146a pro-
duced much less IgE, in the serum of patients with AD, there was detected a 
negative relationship of miR‐146a levels with serum IgE in allergic AD patients 
(Carreras-Badosa et al., 2018). This indicates, that miR-146a is needed for the 
production of IgE, however, when miR-146a is increased, it may act in the 
suppression of inflammation.  
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Similarly to AD, the function of miR-146a has also been studied in PV. It 
has been shown that miR-146a is upregulated in both lesional skin and peri-
pheral blood mononuclear cells (PBMCs) of PV patients and the expression of 
miR-146a positively correlated with IL-17 levels in the lesions and peripheral 
blood (Xia et al., 2012). Another study demonstrated that a G-to-C poly-
morphism (rs2910164) in the miR-146a precursor leading to changes in the 
levels of miR-146a is associated with psoriasis in the Chinese Han population. 
More particularly, it was shown that miR-146a CG and GG genotypes signifi-
cantly increased the risk of PV (Zhang et al., 2014). The same single-nucleotide 
polymorphism (SNP) was also studied in the Swedish PV cohort, in which PV 
patients with the CC genotype among HLA-C*06–negative patients were 
protected from PV compared with those with GC or GG genotypes (Srivastava 
et al., 2017). In the imiquimod-induced mouse model of PV, miR-146a-/- mice 
had an earlier onset and more severe skin inflammation with increased expres-
sion of S100a7, S100a8 and S100a9, Krt16, Il1b, and Cxcr2, epidermal hyper-
proliferation, and increased neutrophil infiltration (Srivastava et al., 2017). 
Recent clinical data support the significant role of miR-146a in PV, where after 
12 weeks of treatment with adalimumab, a significant downregulation of miR‐
146a was observed in PBMCs. Additionally, miR‐146a levels in PBMCs were 
inversely correlated with the PASI reduction induced by adalimumab treatment 
(Mensa et al., 2018). Concordant its anti-inflammatory function in AD and PV, 
it was also shown that subcutaneous pre-administration of miR-146a alleviated 
the ear-swelling and reduced the expression of pro-inflammatory cytokines in a 
mouse model of irritant contact dermatitis, showing that miR-146a could have a 
therapeutic effect in inflammatory skin conditions (Urgard et al., 2016). 
The function of miR-146b has not been studied as in detail in the skin as the 
function of miR-146a. One of the few studies showing the role of miR-146b in 
skin demonstrated that miR-146b directly targets the atypical chemokine 
receptor (ACKR2) that functions as a high-capacity scavenger of proinflam-
matory CC-chemokines in the skin. As miR-146a/b have the same seed sequen-
ce, also miR-146a was able to reduce the expression of ACKR2 (Shams et al., 
2018). It has been shown that miR-146b is one of the miRNAs that is upregu-
lated in systemic sclerosis skin tissues and fibroblasts and additionally in nor-
mal skin fibroblasts and endothelial cells that were stimulated with serum from 
systemic sclerosis patients (Zhou et al., 2017). Considering the importance of 
miR-146a in the suppression inflammation, further studies are still needed to 
delineate novel miR-146a/b targets and to clarify the role of the miR-146 family 
in association with particular skin diseases. 
 
 
 
 
43 
2.6. miR-10 family 
The miR-10 family contains two members miR-10a (miR-10-5p) and miR-10b. 
miR-10a is encoded upstream of Homeobox B4 (HOXB4) within the homeobox 
clusters of developmental regulators on chromosome 17 (Lagos-Quintana et al., 
2003; Tehler et al., 2011). miR-10b is encoded by a region, which is located 
near the HOXD cluster on chromosome 2 (Ma et al., 2007). In human embryo-
nic kidney (HEK) 293 cells, the NF-κB transcription complex subunit p65 is the 
direct regulator of miR-10a expression as it can directly bind the miR-10a pro-
moter in response to retinoic acid (Huang et al., 2010). The expression of miR-
10b is induced by Twist-related protein 1 (TWIST1), which binds directly to the 
putative promoter of MIRN10B (Ma et al., 2007). miR-10a and miR-10b differ 
by only a single nucleotide in the mature sequence that is outside the seed 
sequence and are predicted to share common targets (Tehler et al., 2011). 
It has been shown that miR-10a can regulate the differentiation of cells and 
developmental processes. miR-10a can regulate HOX genes by targeting various 
HOX transcripts including HOXA1 and HOXA3 (Garzon et al., 2006; Han et 
al., 2007). Retinoic acid induced miR-10a has been shown to regulate smooth 
muscle cell differentiation from embryonic stem cells (Huang et al., 2010). 
Accordingly, the function of miR-10a has been studied most in different kinds 
of cancers. For example, miR-10a can regulate the migration and invasion of 
hepatoma (Yan et al., 2013). In esophageal squamous cell carcinoma, miR-10a 
expression was reduced compared with control tissues while the overexpression 
of miR-10a in esophageal squamous cell carcinoma cell lines, EC109 and TE‐3, 
decreased cell proliferation, and enhanced apoptosis. The effects of miR-10a on 
cell proliferation were mediated by targeting T-lymphoma invasion and meta-
stasis-inducing protein 1 (TIAM1) and indicate miR-10a as a tumor suppressor 
(Liu et al., 2018). 
Additionally, there are studies showing the role of miR-10a in the regulation 
of immune responses and inflammation. For example, in arterial endothelial 
cells, miR-10a was shown to target the IκB/NF-κB regulators mitogen-activated 
protein kinase kinase knase 7 (MAP3K7) and β-transducing repeat-containing 
gene (βTRC) thereby regulating the activation of the NF-κB pathway (Fang et 
al., 2010). Another study demonstrates that miR-10a can influence the diffe-
rentiation of CD4+ T cell subsets. Naturally occurring Treg cells that arise in 
the thymus have high miR-10a expression, which was shown to be induced by 
retinoic acid and TGF-β. The targets of miR-10a in T-cells were transcriptional 
repressor Bcl-6 and the corepressor Ncor2, and by that, miR-10a inhibited the 
conversion of inducible Treg cells into follicular helper T cells. In the same 
study, miR-10a was shown to repress the differentiation of the Th17 subset 
indicating that miR-10a has a role in the regulation of the plasticity of T helper 
cells (Takahashi et al., 2012). In inflammatory bowel disease patients, miR-10a 
expression was decreased in the inflamed mucosa compared with healthy cont-
rols. In vitro DC cell cultures, TNF and IFN-γ decreased and TGF-β increased 
miR-10a and IL-12/IL-23p40 and nucleotide-binding oligomerization domain-
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containing protein 2 were identified as direct targets, indicating that miR-10a 
regulates inflammatory responses in DC (Wu et al., 2015).  
 
 
2.6.1. miR-10 family function in the skin 
The function of miR-10b has been studied in the context of various skin cancers 
and inflammatory diseases. It has been shown that the increased expression of 
miR-10b is associated with poor prognosis in melanoma (Bai et al., 2017). 
Additionally, miR-10b was found to be upregulated in aggressive squamous cell 
carcinomas. More particularly, miR-10b was associated with pro-metastatic 
function as it supported cancer stem cell-like properties, like increased adhe-
sion, spheroid formation capacities, and associated cellular outgrowth of im-
mortalized keratinocytes (Wimmer et al., 2020). In the case of ankylosing spon-
dylitis, a common inflammatory rheumatic disease, Th17 cells upregulated 
miR-10b in response to IL-6 and TNF-α. On the other hand, miR-10b regulated 
the cytokine production of Th17 cells and suppressed IL-17A production, at 
least in part through direct inhibition of MAP3K7 expression (Chen et al., 
2017).  
The role of miR-10a in the skin is not well known. There are a few sequen-
cing and array datasets that show the downregulation of miR-10a in PV com-
pared with healthy skin (Joyce et al., 2011; Sonkoly et al., 2007) or upregulation 
in AD (Rebane et al., 2014). It should be noted, miR-10b expression in the 
keratinocytes is significantly lower than that of miR-10a (Rebane et al., 2014). 
From functional studies, it was shown that miR-10a expression is down-
regulated during wound healing and that this downregulation is inhibited in 
diabetic wounds as compared to normal skin wounds. Therefore, the down-
regulation of miR-10a was suggested to support the healing of skin wounds 
(Madhyastha et al., 2012). In line with this, another recent study identified miR-
10a as one of the highest expressed miRNAs in the mouse skin, which was 
downregulated during wound healing (Simoes et al., 2019). Additionally, the 
miR-10 family was the most abundant among those downregulated in psoriatic 
keratinocytes as compared to keratinocytes separated from control skin biopsies 
(Srivastava et al., 2019). However, it should be noted that none of these studies 
showed the function of miR-10a during wound healing nor how miR-10a 
expression is regulated during this process.  
 
 
2.7. Summary of the literature 
Keratinocytes in the epidermis are an essential part of the skin immune regula-
tory network. They participate in the regulation of both, the innate and adaptive 
immune responses by transmitting signals from the environment to the immune 
cells by producing pro-inflammatory chemokines and cytokines as well as anti-
inflammatory ligands (Nestle et al., 2009). In the case of chronic inflammatory 
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skin disease, pro-inflammatory signaling pathways are constitutively activated 
in the keratinocytes. These include the NF-κB signaling pathway, which activa-
tion is needed for many genes involved in cell adhesion, differentiation, growth, 
apoptosis, and acute-phase inflammatory responses (Kunsch & Rosen, 1993; 
Mori & Prager, 1996; Pahl, 1999). Another commonly activated pathway in 
inflammation is the JAK/STAT pathway, which is used by over 60 cytokines 
and growth factors (Howell et al., 2019). As a result of activation of these and 
other signaling pathways, miRNAs like miR-146a/b and miR-10a are expressed 
in keratinocytes. The functional role of miRNAs is to regulate gene expression 
at the post-transcriptional level (Bartel, 2004; Lau et al., 2001; Lee et al., 1993). 
Interestingly, miR-146a/b and miR-10a had been both shown to suppress the 
NF-κB signaling pathway activation. miR-10a was previously shown to target 
IκB/NF-κB regulators MAP3K7 or βTRC in endothelial cells (Fang et al., 
2010). miR-146a/b was demonstrated to target multiple members of the NF-κB 
signaling pathway including IRAK1, TRAF6, and CARD10 (Rebane et al., 
2014; Taganov et al., 2006). Both these miRNAs were detected to be upregu-
lated in keratinocytes from AD patients as compared to controls as well as the 
anti-inflammatory function of miR-146a in AD had been demonstrated (Rebane 
et al., 2014).  
Despite these former publications, several questions have remained to be 
elucidated. First, the previous study describing the anti-inflammatory function 
of miR-146a in AD by targeting the NF-κB suggested that miR-146a effect is 
more general, and therefore it may also have a function in PV (Rebane et al., 
2014). Moreover, a large number of downregulated genes detected from array 
analysis suggested that besides the capacity to suppress the inflammation, miR-
146a may have additional functions in keratinocytes (Rebane et al., 2014). 
Second, at least two previous studies had shown the increased expression of 
miR-146b besides miR-146a in the skin of PV patients (Lovendorf et al., 2015; 
Sonkoly et al., 2007), however, the functional impact of miR-146b in keratino-
cytes was not studied before. As miR-146a/b differ only by two nucleotides on 
the 3′-end of the mature strand and they were predicted to target the same set of 
genes, we could hypothesize that more robust repression of the NF-κB signaling 
pathway may occur when both these miRNAs are present. Thus, we could not 
exclude that miR-146 family members can have individual and/or overlapping 
functions, thereby adding another layer of complexity needed to be explored. As 
besides miR-146a/b, other miRNAs were detected to be differentially expressed 
in keratinocytes from AD patients in our previous array analysis (Rebane et al., 
2014), we proposed that other miRNAs also may influence the disease develop-
ment. As among them, miR-10a was previously shown to target MAP3K7 in 
endothelial cells (Fang et al., 2010) and regulate cell proliferation and differen-
tiation (Garzon et al., 2006; Liu et al., 2018), we choose it for functional studies 
in keratinocytes to explore the relationship with AD. 
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3. AIMS OF THE STUDY 
The overall aim of this study was to characterize the role of miR-146a/b and 
miR-10a in keratinocytes and how they contribute to the development of PV 
and AD, respectively.  
The specific aims were: 
– To characterize miR-146a/b expression and relationship with the target 
genes in the skin of PV patients and role in the regulation of keratinocyte 
proliferation and activation.  
–  To investigate the expression, regulation, and function of putative miR-
146a/b target serpin peptidase inhibitor B2 (SERPINB2) in keratinocytes in 
association with PV.  
–  To describe the localization, regulation, and function of miR-10a in kerati-
nocytes and AD. 
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4. MATERIALS AND METHODS  
4.1. Patients (Study I, II and III) 
Skin samples from patients with PV (Diagnosis Code L40. 0) were collected 
from the Dermatology Clinic of Tartu University Hospital and University Hos-
pital Kiel (Germany). Skin samples from patients with AD (Diagnosis Codes 
L20.0, L20.8, L20.9) or healthy controls were collected only from the Dermato-
logy Clinic of Tartu University Hospital. All participants provided written in-
formed consent and the study was approved by the respective institutionsʼ ethics 
committees (permit numbers 219/T-28 and 267/T-8) and performed according 
to the Declaration of Helsinki Principles. All the participants were unrelated 
Caucasians living either in Estonia or Germany. Control subjects were recruited 
from among health care personnel, medical students, and patients who turned to 
the dermatological outpatient clinic for surgical excision of nevi. None of the 
control subjects had any history of chronic inflammatory skin disease or a 
family history of psoriasis or AD. From each patient with PV or AD, two punch 
biopsy skin samples (3–4 mm in diameter) were taken, one from the marginal 
zone of lesional skin and another from non-sun-exposed non-lesional skin. 
From each control subject, one punch biopsy skin sample (3–4 mm in diameter) 
from non-sun-exposed skin was taken. The skin samples were immediately 
frozen and stored at -80˚C until RNA extraction. For in situ hybridization and 
immunofluorescence, skin biopsy specimens were embedded into the Tissue-
Tek (Thermo Fisher Scientific, Waltham, MA, USA) before freezing.  
In study I and II, the same 22 PV patients and 22 controls were used for RT-
qPCR and correlation analyses. In study I, an additional four PV patient 
samples and three control samples were used for in situ hybridization and 
immunofluorescence. In study II, an additional 1 PV patients and 1 control 
subjects were used for immunofluorescence analysis. The PASI score of the PV 
patients ranged from 7 to 33. The patients were 9 women and 18 men aged 
between 21 to 65 years. The control individuals were 11 women and 15 men 
aged between 20 to 76 years. For study III, 10 AD patients were included in the 
study (5 women and 5 men, age between 22 to 58 years), and 15 control 
samples were used that were gender- and age-matched (7 men, 8 women, age 
20–59 years). Elevated IgE or eosinophilia was detected for 9 out of 10 patients. 
One patient with AD was diagnosed with bronchial asthma.  
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4.2. Cell culture 
4.2.1. Primary Human Epidermal Keratinocytes  
(Study I, II and III) 
Pooled primary human keratinocytes from healthy adults (PromoCell, Heidel-
berg, Germany) were used in the experiments. To passage the keratinocytes, the 
cells were detached with trypsin (Thermo Fisher Scientific) at >80% confluency 
and re-seeded at 20–30% confluency. Trypsin neutralizing solution (Lonza, 
Basel, Switzerland) was used to neutralize the trypsin solution. The keratino-
cytes were used at passages between 5 to 8. Monolayer keratinocyte cultures 
were grown in Keratinocyte-SFM media with supplements, human recombinant 
Epidermal Growth Factor (5 ng/ml) and Bovine Pituitary Extract (50 μg/ml) 
(Thermo Fisher Scientific) and with Penicillin and Streptomycin mixture  
(0.5 U/ml) (Lonza, Basel, Switzerland). To grow the 3D keratinocyte culture in 
air-liquid interface 5×105 cells were seeded on ThinCert Cell Culture Inserts 
(Greiner Bio-One, Kremsmünster, Austria) (0,4 μm pore, 0.33 cm2) on 24-well 
plates using Keratinocyte-SFM medium with supplements and Dulbeccoʼs 
Modified Eagle Medium (both from Thermo Fisher Scientific) containing High 
Glucose, GlutaMAX™, and Pyruvate in 1:1 ratio. To observe the growth and 
monitor the quality of the 3D culture transepithelial resistance was measured 
every 24 hours using Millicell ERS-2 Voltohmmeter (Merk Millipore, Darm-
stadt, Germany). All the cells were grown at 37°C in a humidified incubator 
with 5% CO2 in the air. For monolayer keratinocyte differentiation experiment, 
the cells were grown in the presence of 1.8 mM calcium chloride. 
 
 
4.2.2. Human primary fibroblasts (Study I) 
To culture human primary fibroblasts, a piece of dermis was used, and the 
fibroblasts were isolated by the migration method. The piece of dermis was cut 
into 4×4 mm pieces and attached onto a culture dish, covered with Dulbeccoʼs 
Modified of Eagleʼs Medium (DMEM) (Merck, Darmstadt, Germany) and 
supplemented with 10% fetal bovine serum (Merck) and with Penicillin and 
Streptomycin mixture (0.5 U/ml) (Lonza, Basel, Switzerland). To passage the 
fibroblasts, the cells were taken up with trypsin (Thermo Fisher Scientific) at 
>80% confluency and re-seeded at 20–30% confluency. The fibroblasts were 
grown at low passage numbers (2–3). The cells were grown at 37°C in a humi-
dified incubator with 5% CO2 in the air. 
 
 
4.2.3. Human peripheral blood mononuclear cells (Study I) 
The PBMCs were isolated from freshly collected blood obtained from Blood 
Centre of Tartu University Hospital. PBMCs were prepared by density gradient 
centrifugation on Ficoll-PaqueTM Plus (GE Healthcare, Chicago, IL, USA). 
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4.3. Transfection and stimulation of cells (Study I, II and III) 
Transfection with PepFect14 was used in all three studies. For the transfection, 
2×104 cells were seeded per each well of 12-well plate or 5×103 cells per well of 
96-well plate and after 24 h, the cells were transfected with PepFect14 as 
described in (Urgard et al., 2016). Here briefly, PepFect14 and miRNA mimics, 
siRNA or LNA-inhibitors at 30 or 60 nM concentration were mixed at molar 
ratio 17:1 in a final volume of 100 µl, incubated at room temperature for 1 h, 
mixed with 900 µl of the growth media and applied to the cells in the case of 
12-well plates. For 96-well plates, the same molar ratio was used but the 
miRNA mimics, siRNA or LNA-inhibitors, and PepFect14 were incubated in a 
final volume of 60 μl at room temperature for 1 h, then mixed with 0,54 ml of 
the growth media and shared to the cells in six wells of 96-well plate as six 
replicates were usually done. All the used siRNAs, miRNAs, and LNA-inhibi-
tors are shown in tables 1, 2, and 3 respectively. After 24 h, cells were either 
harvested or stimulated with cytokines for an additional 48 h shown in table 4.  
In study I and III, in addition to PepFect14 transfection siPORT NeoFX 
(Thermo Fisher Scientific) was used. In that case, 2×104 keratinocytes per well 
of 12-well or 5×103 cells per well of 96-well plate were seeded 24 hours before 
the transfection, which was performed according to the manufacturer’s protocol, 
3 µl or 0.3 µl of siPORT NeoFX per well of 12-well or 96-well plate was used, 
respectively. 
If only stimulations were performed, 4×104 cells were seeded per well of 12-
well plate and stimulated after 24 h for an additional 48 h with cytokines shown 
in table 4 or left nonstimulated. In time point analysis, the cells were stimulated 
with indicated cytokines for 6, 12, 24, 48, or 72 h or left nonstimulated. For 3D 
ALI cultures the cells were seeded as described earlier and after 5 days 
stimulated for 48 h with cytokines or left nonstimulated. 
 
 
Table. 1 siRNAs used in the studies. 
 Assay ID/ 
Catalog 
number 
Concen-
tration 
Manufacturer Study 
Silencer Select 
Validated CARD10  
s26577 50 nM  Thermo Fisher Scientific Study I 
30 nM Study II 
Silencer Select 
Validated FERMT1 
s31076 50 nM Thermo Fisher Scientific Study I 
Silencer Select 
Validated IRAK1 
s323 50 nM  Thermo Fisher Scientific Study I 
30 nM Study II 
Silencer Select 
Validated SERPINB2  
s10018 30 nM Thermo Fisher Scientific Study II 
Silencer™ Select 
Negative Control No. 1 
siRNA 
4390843 50 nM Thermo Fisher Scientific Study I 
30 nM Study II 
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Table 2. miRNA mimics used in the studies. 
 Assay 
ID/Catalog 
number 
Concen-
tration 
Manufacturer Study 
Pre-miR™ miRNA 
Precursor Molecules 
Negative Control #1 
AM17110 
 
60 nM Thermo Fisher 
Scientific 
Study I 
30 nM Study III 
Pre-miR™ miRNA 
Precursor hsa-miR-146a-5p 
PM10722/ 
AM17100  
60 nM Thermo Fisher 
Scientific 
Study I 
Pre-miR™ miRNA 
Precursor hsa-miR-10a-5p 
PM10787/ 
AM17100 
30 nM Thermo Fisher 
Scientific 
Study III 
mirVana miRNA Mimic, 
Negative Control #1 
4464058 30 nM  Thermo Fisher 
Scientific 
Study I, 
Study III 
mirVana® miRNA mimic 
has-miR-146b-5p 
MC10105/ 
4464066 
30 nM  Thermo Fisher 
Scientific 
Study I 
mirVana® miRNA mimic 
hsa-miR-10a-5p 
MC10787 
/4464066  
30 nM Thermo Fisher 
Scientific 
Study III 
miRIDIAN miRNA hsa-
miR-146a-5p mimic 
C-300630-03-
0020 
30 nM Dharmacon 
(Lafayette, CO, 
USA) 
Study II 
miRIDIAN miRNA hsa-
miR-146b-5p mimic 
C-300754-03-
0005 
30 nM Dharmacon Study II 
miRIDIAN miRNA Mimic 
Negative Control #1 
CN-001000-
01-20 
30 nM Dharmacon Study II 
 
 
Table 3. LNA-inhibitors used in the studies. 
 Catalog 
number 
Concentration Manu-
facturer 
Study 
hsa-miR-146 miRCURY 
LNA™ miRNA Power 
Family Inhibitor 
YFI0450021 
 
30 nM Qiagen 
(Hilden, 
Germany) 
Study I, 
Study II 
hsa-miR-146a-5p miRCURY 
LNA miRNA Inhibitor 
YI04100676 30 nM Qiagen Study I 
hsa-miR-10a-5p miRCURY 
LNA miRNA Inhibitor 
YI04101337 
 
10 nM or 30 nM Qiagen Study III 
Negative control A 
miRCURY LNA miRNA 
Inhibitor Control 
YI00199006
  
30 nM Qiagen Study I, 
Study II 
10 nM or 30 nM Study III 
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Table 4. Cytokines used in the studies. 
Cytokine Concentration Manufacturer Study 
IFN-γ  10 ng/ml PeproTech (London, UK) Study I, Study II,  
Study III 
HB-EGF  25 ng/ml PeproTech Study III 
IL-1β  10 ng/ml PeproTech Study I, Study III 
IL-4  40 ng/ml PeproTech Study III 
IL-6 20 ng/ml PeproTech Study II 
IL-13 50 ng/ml PeproTech Study III 
IL-17A  10 ng/ml PeproTech Study I, Study II, Study 
III 
IL-20 20 ng/ml PeproTech Study II 
IL-22  10 ng/ml PeproTech Study I  
20 ng/ml Study III 
IL-23 20 ng/ml Thermo Fisher Scientific Study II 
Retinoic acid 
(ATRA) 
300 ng/ml Merck  Study III 
TGF-β  20 ng/ml R&D Systems 
(Minneapolis, MN, USA) 
Study III 
TNF-α  25 ng/ml PeproTech Study I, Study II,  
Study III 
 
 
4.4. Isolation of RNA, cDNA synthesis and RT-qPCR  
(Study I, II and III) 
All skin biopsies were submerged Qiazol (Qiagen, Hilden, Germany) cell lysis 
reagent and homogenized with Precellys 24 homogenizer (Bertin Instruments, 
Montigny-le-Bretonneux, France) at 4°C. Total RNA from frozen skin samples 
was isolated using the miRNeasy mini kit (Qiagen, Hilden, Germany) according 
to the manufacturer´s protocols. Total RNA was extracted from in vitro cell 
culture samples with Direct-zol™ RNA MiniPrep Kit (Zymo Research, Irvine, 
CA, USA) (Study I and III), miRNeasy Mini Kit (Qiagen) (Study I, III) or total 
RNA mini kit (AA Biotechnology, Gdynia, Poland) (Study II) according to the 
manufacturer´s protocols. In-column DNase digestion was performed with 
DNase (Zymo Research) or with RNase-Free DNase Set (Qiagen). RNA con-
centration and quality were assessed with NanoDrop 2000c (Thermo Fisher 
Scientific) and Agilent 2100 Bioanalyzer, using Agilent RNA 6000 Nano Kit 
(Agilent Technologies, Santa Clara, CA, USA). 
miRNA expression levels were quantified with TaqMan® miRNA Reverse 
Transcription Kit and TaqMan® miRNA Assays (TaqMan® miRNA Assays 
hsa-let-7a, TaqMan® miRNA Assays hsa-miR-146a, TaqMan® miRNA Assays 
hsa-miR-146b or TaqMan® miRNA Assays hsa-miR-10a) (all from Thermo 
Fisher Scientific) and 5× HOT FIREPol® Probe qPCR Mix Plus (ROX) (Solis 
BioDyne, Tartu, Estonia). That were all used according to the manufacturer’s 
52 
protocol. let-7a was used for normalization and relative expression was calcu-
lated using the ΔΔCt method. For quantification of mRNA expression levels, 
cDNA was synthesized from 0.1–1 µg of total RNA using oligo-dT (TAG 
Copenhagen, Frederiksberg, Denmark), RevertAid Reverse Transcriptase and 
RiboLock RNase Inhibitor (Thermo Fisher Scientific). For qPCR, 5x HOT 
FIREPol EvaGreen qPCR Supermix (Solis BioDyne) was used. PCR primers 
were designed with the assistance of Primer 3 (Untergasser et al., 2012) and 
were ordered from TAG Copenhagen. A list of used primers can be seen in 
table 5. Target gene expression was normalized to EEF1A1 using ΔΔCt calcula-
tion. Machines used were ABI Prism 7900 (Thermo Fisher Scientific) or Viia7 
(Thermo Fisher Scientific). 
 
 
Table 5. Used primers. 
Gene Forward Reverse 
CARD10 5´-AGTGTGCCCAGCGGAAAGCC-3’ 5’-GATGGCCCGGATCCTGCTGC-3’ 
CCL5 5´-AGTCGTCTTTGTCACCCGAAA-3’ 5’-TCTCCATCCTAGCTCATCTC 
CAA-3’ 
EEF1A1 5´-CCACCTTTGGGTCGCTTTGCTGT-3’ 5’-TGCCAGCTCCAGCAGCCTT 
CTT-3’ 
FERMT1 5’-TGATGCAGCCACCGGGATTCCA-3’ 5’-CGA TGACCACCTGCCGGGT 
TTC-3’ 
IL-8 5’-GCAGCTCTGTGTGAAGGTG 
CAGTT-3’ 
5’-TTCTGTGTTGGCGCAGTGTG 
GTC-3’ 
IRAK1 5’-CACCTTCAGCTTTGGGGTGGT 
AGTG-3’ 
5’-CCAGCCTCCTCAGCCTCCTCT-3’ 
Ki67 5’-AAAGAGTGGCAACCTGCCTT-3’ 5’-TTTGCAACAATCAGATTTGCT 
TCCG-3’ 
KRT10 5’-TCCCAACTGGCCTTGAAACAAT 
CCC-3’ 
5’-AGAGCTGCACACAGTAGCG 
ACCT-3’ 
MAP3K7 5’-AGCCTGCTTGAATCCAGTGT-3’ 5’-TTGCGTGGGCAGCAGTATAA-3’ 
NUMB 5’-AATGCCTTCAGCACACCTGA-3’ 5’-AGTC AGTGCCATTAGCTTG 
GAA-3’ 
SERPINB2 5’-GGATGGTCCTGGTGAATGCT-3’ 5’-TGCGCTGAGCCGAGTTTAC-3’ 
 
 
4.5. Immunofluorescence (Study I and II)  
Immunofluorescence was performed on either cryosections of skin biopsy 
samples or on primary human keratinocytes. For skin sample collection for 
immunofluorescence analysis, the bunch biopsy samples of healthy controls, 
nonlesional, and lesional skin of PV patients were snap-frozen in TissueTek 
(Thermo Fisher Scientific). Immunofluorescence staining of FERMT1 or 
SERPINB2 was performed on frozen skin sections of 10 or 5 µm, respectively. 
For the staining of SERPINB2 in keratinocytes, the cells were seeded on cover-
slips on a 24-well plate. The sections or cells were fixed with 4% formaldehyde 
in PBS for 10 min, permeabilized with 0.1% Triton-X-100 in PBS for 10 min, 
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and blocked with 10% goat serum (Thermo Fisher Scientific) and 0.5% BSA 
(Merck, Darmstadt, Germany) in PBS for 1 h. The skin sections or cells were 
further incubated for 1 hour either with rabbit polyclonal anti-FERMT1 anti-
body (HPA041966) (Atlas Antibodies, Stockholm, Sweden) or mouse mono-
clonal anti-SERPINB2 antibody (MAB8550) (R&D Systems, Minneapolis, 
MN, USA). The omission of the primary antibody was used as a negative 
control. Alexa-488 labeled anti-rabbit-IgG (Thermo Fisher Scientific) with a 
dilution of 1:2000 or Alexa-488 labeled anti-mouse-IgG (Thermo Fisher Scien-
tific) at dilution of 1:1000 were used respectively as secondary antibodies. Be-
fore and after antibody incubations, samples were washed 3×5 min with PBS. 
Further, the slides were stained with 4′,6-diamidino-2-phenylindol (DAPI) 
(Roche, Basel, Switzerland) (1μg/mL) for 10 min. After that, the slides were 
washed twice with PBS and were mounted either with StayBrite Hardset 
Mounting Medium (Biotium, Fremont, CA, USA) or fluorescent mounting me-
dium (Agilent, Santa Clara, CA, United States) and analyzed with Leica 
DM5500 B microscope (Leica Microsystems, Wetzlar, Germany). 
 
 
4.6. In situ hybridization (ISH) (Study I and III) 
In study I and III, miRNA ISH Buffer, Controls Kit, and miRCURY LNA™ 
Detection probes (all from Qiagen) were used according to the manufacturer’s 
protocol. In study I, ISH was performed on 10 µm frozen sections using 5`-DIG 
and 3`-DIG-labeled hsa-miR-146a-5p (619856-360), hsa-miR-146b (615935-
360) miRCURY LNA™ Detection probes. In study III, ISH was performed on 
6 μm frozen skin sections using 5`-DIG and 3`-dig-labeled miRCURY LNA™ 
Detection probes: hsa-miR-10a-5p (612528-360) and Custom Detection Probe 
as a scrambled control (339115). Prehybridization, hybridization, and washing 
were performed at 50 °C for miR-146a and 48 °C for miR-146b and miR-10a. 
For detection, slides were incubated with alkaline phosphatase-conjugated 
sheep anti-DIG-AP (1:1500, Roche) for 1h at room temperature. The staining 
was visualized by adding BM purple alkaline phosphatase substrate (Roche).  
 
 
4.7. Western blot (Study I) 
The human primary keratinocytes were lysed using 1× Laemmli buffer and then 
boiled at 95°C for 5 minutes before the loading to the gel. A total of 10 μl of 
protein solution was loaded in each line of 10% SDS PAGE gel. Antibodies 
were diluted in Tris-buffered saline containing 0.05% Tween 20 and 5% milk. 
Primary antibodies were used at the following dilutions: mouse monoclonal 
anti-GAPDH 1:1000 (Santa Cruz Biotechnology, Dallas, TX, USA) and rabbit 
polyclonal anti-FERMT1 antibody 1:250 (HPA041966, Atlas Antibodies). For 
secondary antibodies, anti-rabbit and -mouse IgG horseradish peroxidase-
conjugated antibodies were used 1:2000 (Cell Signaling Technology, Danvers, 
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MA, USA). For signal detection, Amersham ECL Select Western blotting kit 
(GE Healthcare) was used according to the manufacturer’s protocol. The results 
were visualized using ImageQuant™ RT ECL™ (GE Healthcare) and were 
quantified using ImageJ software. The mean intensity of the background value 
was subtracted from the mean intensity of each protein band and then norma-
lized against the mean values of GAPDH. 
 
 
4.8. The enzyme-linked immunosorbent assay (ELISA) 
(Study II) 
For study II, the quantity of secreted SERPINB2, CCL5, and IL-8 were measured 
from the keratinocyte culture supernatants using the Serpin B2 DuoSet ELISA kit 
(R&D Systems, Minneapolis, MN, USA) or the CCL5 or IL-8 ELISA MAX™ 
Deluxe sets (BioLegend). ELISAs were performed according to the manu-
facturer’s protocol. The data were acquired with Ledetect 96 Microplate reader 
(Labexim Products, Lengau, Austria) and the concentrations were calculated by 
using the Four Parameter Logistic Regression model in an online analysis 
software Myassays.com (MyAssays Limited, Brighton, United Kingdom). 
 
 
4.9. Luminescent Cell Viability Assay (Study I and III) 
Keratinocytes were transfected on 96-well plates as described previously. For 
study III, the cell proliferation was analyzed after 72h of the transfection of 
miR-10a and for study I after 24h of the transfection of miR-146a/b. CellTiter-
Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA) was 
used according to the manufactureʼs protocol. Luminescent Cell Viability Assay 
measures luciferase activity that is proportional to the amount of cellular ATP. 
 
 
4.10. Thymidine Incorporation Assay (Study I) 
Keratinocytes were transfected with miR-146a or negative control mimics on 
96-well plates as described previously. Cytokines were added after 24 hours and 
a radioactive nucleoside 3H thymidine (Hartmann Analytic, Braunschweig, Ger-
many) at an end-concentration of 1 µCi/ml after 48 hours. During cell-division, 
3H thymidine was incorporated into the replicating DNA. After 14 hours, cells 
were harvested onto a glass-fiber filter, mounted with a cocktail containing 
scintillation liquid, and the counts were monitored using a scintillation beta-
counter to measure the radioactivity in DNA recovered from the keratinocytes 
to determine the extent of cell division that has occurred. β-counts of the control 
cells were in the range of 2.7 × 104 and 1.2 × 106 counts per minute.  
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4.11. Cell cycle analysis (Study III) 
For cell cycle analysis, the cells were first trypsinized and collected 48 h after 
transfection with miR-10a or negative control mimics. The cells were fixed for 
30 minutes with ice-cold 70% ethanol, permeabilized in 0,1 % Triton X-100 in 
PBS for 10 minutes at room temperature, and stained with DAPI (1 µg/ml). Cell 
cycle phase distribution was determined with BD LSRFortessa™ cell analyzer 
(BD Biosciences Franklin Lakes, NJ, USA) by quantifying DAPI intensity and 
further analyzed using ModFit LT™ Software 2.5.1 (Verity Software House, 
Topsham, ME, USA). 
 
 
4.12. Proliferation assay with Click-iT™ EdU Cell 
Proliferation Kit (Study III) 
Click-iT® EdU Cell Proliferation Alexa Fluor® 488 Flow Cytometry assay 
(Thermo Fisher Scientific) was performed 48 h after the transfection of human 
primary keratinocytes with miR-10a or negative control mimics according to the 
manufacturer’s instructions. EdU was added to the cells 2 hours before har-
vesting the cells. For analysis, BD LSRFortessa™ cell analyzer (BD Bioscien-
ces) was used.  
 
 
4.13. Cloning and Luciferase assay (Study I) 
Two FERMT1 3’UTR fragments, containing binding sites for miR-146a or the 
corresponding mutant binding sites of FERMT1 were cloned into the pmirGLO 
Dual-Luciferase miRNA Target Expression Vector (Promega) using the PCR 
primers containing NheI and SalI sites. The used cloning primers are shown in 
table 6. For Luciferase assay, human embryonic kidney epithelial cells HEK293 
were transfected for 24 hours with 30 nM miR-146a and control (Pre-miR™ 
Precursors Molecules hsa-miR-146a or Negative Control #1, Thermo Fisher 
Scientific) and 50 ng of the reporter plasmid using siPORT NeoFX (Thermo 
Fisher Scientific) according to the manufacture’s manual. Firefly and renilla 
luciferase activities were measured using the Dual-Luciferase® Reporter Assay 
System (Promega). Firefly luciferase activities were normalized to the values of 
the renilla luciferase. 
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Table 6. Used cloning primers. 
Site Forward Reverse 
FERMT1-1 
3ʼUTR 
5’-ATTGCTAGCACCCACTGC 
TGGCACATCCCT-3’ 
5’-ATTGTCGACGCAGTTCCAT 
GAAGG ACAGGCG-3’ 
FERMT1-2 
3’UTR 
5’-ATAGCTAGCATTAACAGCTG 
CCTGAATT-3’ 
5’-ATAGTCGACAAGTCTGTCT 
CTAT GTGGCT-3’ 
FERMT1-1 
3'UTR for 
mut 
5’-TGGTTACAGTAGTC 
TGACTTGC-3’ 
5’-GCAAGTCAGACTACTGT 
AAC-3’ 
FERMT1-2 
3ʼUTR for 
mut 
5’-ATTTTTCAGTAGTCCTAG 
GATG-3’ 
5’-CATCCTAGGACTACT 
GAAAAAT-3’ 
 
 
4.14. Array, pathway and target analysis  
(Study I and Study III) 
For study I, a previously published dataset E-MTAB-1739, in which miR-146a 
or negative control mimics were transfected to keratinocytes and the cells were 
stimulated with IFN-γ or TNF-α or left nonstimulated (Rebane et al., 2014) and 
where mRNA profiling was done with Illumina HumanHT-12 Expression 
BeadChip (Illumina, San Diego, CA, USA) was used. The dataset was reana-
lyzed to determine the effect of miR-146a in nonstimulated keratinocytes. For 
study III, mRNA profiling of cells where miR-10a or negative control mimics 
were transfected to keratinocytes and the cells were stimulated with IL‐1β or 
left nonstimulated, was done with Illumina HumanHT-12 Expression Bead-
Chips version 4 (Illumina) and data analyzed with Illumina GenomeStudio 
V2009.1 Gene Expression Module using Quantile normalization and back-
ground subtraction with Illumina custom errors model. For both studies, addi-
tional analyses and visualizations were performed using Microsoft Excel and 
Multi Experiment Viewer 4.8.1. Pathway analysis was performed with g:Pro-
filer (http://biit.cs.ut.ee/gprofiler) (Reimand et al., 2007), which estimates the 
significance of the overlap between the functional groups and the list of studied 
genes by calculating enrichment P-value using Fisherʼs one-tailed test. For 
study III, additionally, genes with average expression values below 50 or 
average detection P values above 0.05 in all conditions, were discarded. The re-
maining genes were sorted based on gene expression fold change between 
control transfected and miR-10a transfected cells and only the 200 most up-
regulated genes were used in g:Profiler analysis. For both studies, putative 
direct targets for miR-146a or miR-10a were selected using Targetscan 
(http://www. targetscan.org/vert_71/) search, choosing only highly conserved 
and those with better context score (<-0.15) (Agarwal et al., 2015; Lewis et al., 
2005). 
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4.15. Statistical analyses (Study I, II and III) 
Statistical analyses were performed with GraphPad Prism 5 or 6 (GraphPad 
Software, San Diego, CA, USA) by ANOVA when more than 2 conditions were 
compared or Student’s t-test, otherwise. For the linear regression analysis, Pear-
son’s chi-squared test was used. Results were considered significant at P<0.05. 
Data are presented as mean with the standard error of the mean (SEM).  
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5. RESULTS 
5.1. Both miR-146a and miR-146b are upregulated in the 
skin of PV patients and in response to pro-inflammatory 
cytokines in keratinocytes (Study I) 
The upregulation of miR-146a/b in PV has been shown previously by miRNA 
expression profiling (Sonkoly et al., 2007). To confirm the previous array result, 
we used RT-qPCR revealing the increased expression of miR-146a/b in the 
lesional skin of PV patients compared with healthy controls (Figure 11A). To 
determine the localization of miR-146a/b in the tissue, we performed in situ 
hybridization analysis of skin sections from healthy controls, non-lesional and 
lesional skin of PV patients. While only modest miR-146a expression, which 
was still stronger than that of miR-146b, was found in the epidermis of the 
control skin, a robust miR-146a signal was detected in the epidermis of PV 
patients lesional skin sample (Figure 11B). The expression of miR-146a in PV 
patientsʼ lesional skin was the highest in the granular layer of the epidermis. 
Comparatively, miR-146b expression in the lesional skin of PV patients was 
lower than that of miR-146a, and therefore, its localization was not so clearly 
defined (Figure 11B). Interestingly, in one of the PV patients, the expression of 
miR-146b was higher in the dermis compared with the epidermis of the lesional 
skin.  
Next, we compared the levels of miR-146a/b in the healthy skin with the 
levels of miR-146a/b in human primary keratinocytes, fibroblasts, and peri-
pheral blood mononuclear cells. Compared with the skin, the levels of miR-
146a/b were lower in the keratinocytes and fibroblasts, however, highest in the 
peripheral blood mononuclear cells (Figure 11C). To delineate which cytokines 
might be responsible for the increased miR-146a/b levels in the skin, human 
primary keratinocytes in proliferating or differentiating conditions and fibro-
blasts were stimulated with different pro-inflammatory cytokines. In monolayer 
keratinocyte and fibroblast cultures, miR-146a was upregulated in response to 
IL-17A, TNF-α and, IL-1β (Figure 12A, 12B), while miR-146b was upregulated 
in response to IFN-γ in keratinocytes and response to IL-1β in fibroblasts (Fi-
gure 12A, 12B). In the keratinocyte 3D differentiation model, miR-146a was 
upregulated in response to IL-17A, TNF-α, and, IL-1β and miR-146b with IFN-
γ and IL-22 (Figure 12C). To evaluate the reliability of the 3D model, the trans‐
epithelial electrical resistance (TER) was measured every 24 hours (Figure 
12D). These data together demonstrate that miR-146a/b is elevated in the 
lesional skin of PV patients and upregulated by pro-inflammatory cytokines in 
keratinocytes and fibroblasts. 
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Figure 11. The expression of miR-146a/b is increased in the skin of PV patients. A) 
Relative expression of miR-146a/b in the nonlesional (Ps NL) and lesional (Ps L) skin 
of PV patients and healthy controls (Control). The expression of miR-146a/b was 
measured with RT-qPCR. B) In situ hybridization images from nonlesional (Ps NL) and 
lesional (Ps L) skin of PV patients and healthy controls. The expression of miR-146a/b 
is marked in blue. Bar = 75 μm. The line between the epidermis and dermis is indicated 
with a dashed line. C) Relative expression of miR-146a/b in the skin, human primary 
keratinocytes (KC), fibroblasts (Fib), and peripheral blood mononuclear cells (PBMCs), 
(n = 5). The expression of miR-146a/b was measured with RT-qPCR. Data are shown as 
the mean ± SEM, student’s t-test, *P < 0.05, **P < 0.01. 
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Figure 12. The expression of miR-146a/b in human primary keratinocytes and 
transepithelial resistance measurements of keratinocyte 3D cultures. A) Human 
monolayer keratinocytes (KC 2D), B) human primary fibroblasts, C) reconstituted 
epidermis (KC 3D) were stimulated with shown cytokines for 48 hours or left 
nonstimulated (NS). The expression of miR-146a/b was measured with RT-qPCR. Data 
are shown compared with the mean expression of miR-146a in NS cells (=1) (n = 4). D) 
Transepithelial resistance measurements (TER) of keratinocyte 3D cultures. At day 0, 
50 000 KCs were seeded per each well. The apical media was removed on day 4 (a) and 
after 24 hours (b) the KC 3D cultures were stimulated with indicated cytokines for 48h 
or left nonstimulated (NS). Data are shown as the mean ± SEM, student’s t-test, *P < 
0.05, **P < 0.01. 
 
 
 
5.2. miR-146a/b inhibit keratinocyte proliferation (Study I) 
Increased keratinocyte proliferation is a known feature of both AD and PV 
(Dainichi et al., 2018). Interestingly, a pathway analysis of a previously pub-
lished array data (Rebane et al., 2014) revealed that proliferation-related genes 
(Figure 13A) were enriched among the set of 102 genes suppressed by miR-
146a in nonstimulated keratinocytes (Study I, Supplementary Table S2). Next, 
we did a 3H thymidine assay to assess the effect of miR-146a on keratinocyte 
proliferation. We transfected keratinocytes with either miR-146a mimics or 
control or miR-146a inhibitor (LNA-146a) or control LNA to suppress the 
endogenous levels of miR-146a and stimulated keratinocytes with TNF-α or 
IFN-γ or left nonstimulated. Figure 13B demonstrates that miR-146a over-
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expression led to reduced keratinocyte proliferation in nonstimulated cells while 
in the case of inhibition of miR-146a, cell proliferation increased in all condi-
tions (Figure 13C). To further confirm our results and to estimate the effect of 
miR-146b, we next carried out ATP dependent assay where Luciferase activity 
is measured as the outcome. Figure 13D demonstrates that miR-146b can sup-
press cell proliferation to a similar extent as miR-146a and if endogenous levels 
of both miRNAs are reduced by LNA targeting both miR-146a/b, there is an 
increase in keratinocyte proliferation. These data together demonstrate that 
miR-146a/b inhibit the proliferation of primary keratinocytes.  
 
 
 
 
Figure 13. miR-146a/b inhibit proliferation of human primary keratinocytes. A) 
Keratinocytes were transfected with control or miR-146a for 24 hours and then 
stimulated with IFN-γ or TNF-α for 48 hours or left nonstimulated (NS). Log2 values of 
expression signals are mean-centered for each gene separately. Asterisks mark the 
proposed miR-146a direct targets. B, C) Keratinocytes were transfected either (B) with 
control or miR-146a or (C) with control LNA (Control) or miR-146a inhibitor (LNA-
146a) for 24 hours and then stimulated with IFN-γ or TNF-α for 24 hours or left non-
stimulated (NS). 3H thymidine was added for another 14 hours. D) Keratinocytes were 
transfected either with control or miR-146a or miR-146b or with control LNA (Control) 
or LNA inhibitor for miR-146a/b (LNA-146) for 24 hours and then the proliferation 
assay was performed. Data are shown as the mean ± SEM, student’s t-test, *P < 0.05, 
**P < 0.01. 
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5.3. miR-146a/b putative target genes are  
upregulated in PV (Study I and III) 
It is previously shown that miR-146a directly targets members of the NF-κB 
pathway like IRAK1 and CARD10 and CCL5 (Crone et al., 2012; Rebane et al., 
2014; Taganov et al., 2006) and it also inhibits IL-8 (Meisgen et al., 2014; 
Rebane et al., 2014). In addition, we choose for further studies FERMT1 and 
SERPINB2 as they both were downregulated by miR-146a in array analysis and 
predicted to be putative direct miR-146a targets by Targetscan (Agarwal et al., 
2015; Lewis et al., 2005). Additionally, they could potentially influence 
disease-related processes in PV as FERMT1 had been previously associated 
with keratinocyte adhesion, proliferation, and migration (Herz et al., 2006; Lai-
Cheong et al., 2009) and SERPINB2 had been demonstrated to have protease 
inhibitor function (Kruithof et al., 1995). From the tested genes, IRAK1, CCL5, 
IL-8, FERMT1, and SERPINB2 were detected to be up-regulated in the lesional 
skin of PV patients compared with healthy controls and nonlesional skin of PV 
patients (Figure 14). FERMT1 and SERPINB2 were also upregulated in the 
non-lesional skin. From the tested genes, only CARD10 was downregulated in 
the lesional skin of PV patients compared with healthy controls. These data 
indicate that both miR-146a/b and putative target genes are upregulated in the 
skin of PV patients because of inflammation-associated signaling and that in-
creased level of miR-146a/b is not sufficient to suppress the targets to the level 
characteristic to non-inflamed condition.  
 
 
Figure 14. The expression of miR-146a/b target genes is changed in PV patientsʼ 
skin. Relative mRNA expression in the nonlesional (Ps NL) and lesional (Ps L) skin of 
PV patients compared with the mean of healthy controls (Control). Data are shown as 
the mean ± SEM, student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001.  
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5.4. miR-146a may regulate the proliferation of 
keratinocytes through FERMT1 (Study I) 
Among putative miR-146a target genes, FERMT1 (also known as Kindlin-1) 
was previously shown to act as a positive regulator of keratinocyte proliferation 
(Herz et al., 2006). In addition, it was known that mutations in the FERMT1 
gene cause Kindler syndrome characterized by multiple skin problems, in-
cluding blistering, premature aging, and increased cancer risk (Duperret & 
Ridky, 2014). Thus, we next performed immunofluorescence analysis showing 
FERMT1 protein expression was the highest in the basal layer of keratinocytes 
and with increased expression in the lesional skin of PV patients (Figure 15A). 
To confirm the effect of miR-146a on FERMT1 expression, keratinocytes were 
transfected with miR-146a and stimulated with TNF-α, IFN-γ, IL-17A, or left 
nonstimulated followed by RT-qPCR and western blot. In most of the condi-
tions, FERMT1 expression was suppressed by miR-146a both at mRNA (Figure 
15B) and protein level (Figure 15C). Based on Targetscan (Agarwal et al., 
2015; Lewis et al., 2005) prediction, two putative miR-146a binding sites in the 
3’ untranslated region (3’ UTR) of FERMT1 mRNA was found. Both these 
binding sites together with flanking areas or the same areas with the mutated 
binding sites were inserted into the luciferase reporter vector. Following 
luciferase assays demonstrated that the overexpression of miR-146a led to the 
suppression of luciferase activity of the reporters containing FERMT1 3’ UTR 
regions with miR-146a binding sites but not with the mutant versions (Figure 
15D). The vector containing CARD10 3’UTR was used as a positive control 
(Crone et al., 2012; Rebane et al., 2014). These results demonstrate that 
FERMT1 is one of the targets through which miR-146a may mediate the effect 
on keratinocyte proliferation. 
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Figure 15. Positive regulator of proliferation FERMT1 is upregulated in PV and is 
a direct target of miR-146a. A) Immunofluorescence analysis of FERMT1 expression 
(Green) in the nonlesional (Ps NL) and lesional (Ps L) skin of PV patients and healthy 
controls (Control). DAPI labeling is blue. The white line indicates the border between 
epidermis and dermis. White bar=50 µm. B, C) Keratinocytes were transfected with 
control or miR-146a for 24 hours and then stimulated with shown cytokines for 48 
hours or left nonstimulated (NS). B) Relative FERMT1 expression was measured by 
RT-qPCR. C) FERMT1 protein expression was measured by western blot. D) HEK293 
cells were transfected with control or miR-146a for 24 hours. The relative firefly lucife-
rase (LUC) activity is normalized to the value of control miRNA and empty vector 
(Control; =1) (n = 8). Data are shown as the mean ± SEM, student’s t-test, *P < 0.05, 
**P < 0.01. 
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5.5. SERPINB2 is indirectly suppressed by miR-146a and has 
an anti-inflammatory effect in keratinocytes (Study III) 
The function of SERPINB2 in the skin was not well understood. To delineate its 
role in the skin, we first visualized SERPINB2 expression by immunofluore-
scence analysis from skin biopsies of healthy controls, non-lesional, and lesio-
nal skin of PV patients. In healthy controls and non-lesional skin of PV patients, 
SERPINB2 expression was localized in the granular layer (Figure 16A). In the 
case of lesional skin, SERPINB2 expression was detectable all over the epider-
mis with the strongest expression in the cornified layer (Figure 16A). Additio-
nally, we were able to confirm that there was a positive relationship between 
PASI and SERPINB2 mRNA expression in lesional skin samples from PV pa-
tients (Figure 16B). Interestingly, we detected a negative relationship between 
SERPINB2 mRNA and miR‐146a even though both miR-146a and SERPINB2 
were upregulated in the lesional skin of PV patients (Figure 16C). Next, we 
stimulated human primary keratinocytes with psoriasis‐related cytokines. From 
the tested cytokines SERPINB2 expression was strongly upregulated in respon-
se to IFN‐γ and TNF‐α and slightly by IL-6 (Figure 16D). The upregulation of 
SEPRINB2 in response to IFN‐γ and TNF‐α was confirmed on protein level by 
immunofluorescence analysis (Figure 16E). Also, there was an increase in the 
levels of secreted SERPINB2 in response to IFN‐γ and TNF‐α measured by 
ELISA (Figure 16F). Inhibition of the expression of SERPINB2 itself by 
siRNAs led to the increased mRNA levels of IL‐8 when stimulated with TNF‐α 
and CCL5 when stimulated with IFN‐γ (Figure 16G). Using the supernatants 
from the same experiment, we detected increased levels of IL‐8 in nonsti-
mulated conditions and when stimulated with TNF‐α and increased CCL5 when 
stimulated with IFN‐γ when SERPINB2 expression was inhibited (Figure 16H). 
Together, these results show that SERPINB2 is upregulated in the lesional skin 
of PV patients and response to pro-inflammatory cytokines. Additionally, these 
results imply that SERPINB2 has an anti‐inflammatory function in keratino-
cytes as it can suppress the levels of pro‐inflammatory chemokines IL‐8 and 
CCL5. 
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Figure 16. SERPINB2 is increased in the skin of PV patients and has an anti-in-
flammatory effect in keratinocytes. A) Immunofluorescence analysis of SERPINB2 
expression (green) in the nonlesional (Ps NL) and lesional (Ps L) skin of PV patients 
and healthy controls (Control). DAPI labeling is blue. The white line indicates the outer 
border of the stratified layer. The red line indicates the border between epidermis and 
dermis. White bar=25 µm. B) Linear regression analysis between SERPINB2 and PASI 
in the lesional skin of PV patients. 95% confidence intervals (CI) are shown as a dotted 
line. Data is presented on the log10 scale. C) Linear regression analysis between 
SERPINB2 and miR-146a in the lesional skin of PV patients. 95% confidence intervals 
(CI) are shown as a dotted line. Data is presented on the log10 scale. D-F) Human 
keratinocytes were stimulated with shown cytokines for 48 hours or left nonstimulated 
(NS). D) The expression of SERPINB2 was measured with RT-qPCR. E) SERPINB2 
level in keratinocyte supernatants was measured by ELISA. F) Immunofluorescence 
analysis of SERPINB2 expression (green) in the stimulated keratinocytes. DAPI 
labeling is blue. White bar=25 µm. G,H) Keratinocytes were transfected either with 
control siRNA (Control) or siRNA targeting SERPINB2 and after 24 h stimulated with 
IFN‐γ or TNF‐α for 48 h or left non‐stimulated (NS). The expression of indicated 
chemokines was measured with RT-qPCR (G) or by ELISA (H). Data are shown as the 
mean ± SEM, student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001. 
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5.6. miR-146a and miR-146b have a similar capacity to 
suppress psoriasis-related target genes (Study I and III) 
To explore whether the miR-146b effect on the targets is indeed similar to miR-
146a, we transfected keratinocytes with miR-146a, miR-146b, or control in 
three conditions, using cells left nonstimulated or stimulated with TNF-α or 
IFN-γ and analyzed mRNA levels of CARD10, IRAK1, CCL5, IL-8, FERMT1, 
and SERPINB2. In most cases, miR-146a and miR-146b suppressed the mRNA 
expression of studied genes and had a similar effect in tested cytokine condi-
tions (Figure 17). These results indicate that miR-146a/b target similar genes to 
the same extent in keratinocytes. 
 
 
Figure 17. miR-146a/b inhibit psoriasis-related genes in keratinocytes. Keratino-
cytes were transfected with control or miR-146a or miR-146b for 24 hours and then 
stimulated with IFN-γ or TNF-α for 48 hours or left nonstimulated (NS). Relative 
mRNA expression was measured by RT-qPCR. Data are shown as the mean ± SEM, 
student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001. 
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5.7. The endogenous level of miR-146a/b is sufficient to 
suppress the target genes in the keratinocytes  
(Study I and III) 
To clarify whether the endogenous level of miR-146a/b is sufficient to suppress 
the target genes in the keratinocytes, we used LNA-miR-146 family inhibitor 
suppressing both, miR-146a/b. Once again, we did this in three conditions, in 
cells left nonstimulated or stimulated with TNF-α or IL-17A. Except in the case 
of SERPINB2 where the cells were left nonstimulated or stimulated with TNF-α 
or IFN-γ instead of IL-17A as IL-17A did not affect SERPINB2 expression and 
IFN-γ had the strongest effect on SERPINB2 levels. In all tested conditions the 
suppression of miR-146a/b led to the increased expression of the target genes 
IRAK1, CARD10, CCL5, and IL-8 (Figure 18). However, in the case of 
SERPINB2, the effect of miR-146a/b suppression was only visible when the 
cells were stimulated with IFN-γ (Figure 18). These data demonstrate that 
endogenous levels of miR-146a/b are sufficient to have an effect on target genes 
in keratinocytes as well as further suggests that miR-146a/b have the capacity to 
suppress the studied target genes also in the skin of PV patients. 
 
 
Figure 18. Inhibition of miR-146a/b endogenous levels leads to increased expres-
sion of psoriasis-related genes in keratinocytes. Keratinocytes were transfected with 
control LNA (Control) or LNA inhibitor for miR-146a/b (LNA-146) for 24 hours and 
then stimulated with shown cytokines for 48 hours or left nonstimulated (NS). Data are 
shown as the mean ± SEM, student’s t-test, *P < 0.05, **P < 0.01. 
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5.8. miR-10a is upregulated in the skin of AD patients and  
is downregulated in differentiated keratinocytes  
(Study II) 
As previous miRNA profiling demonstrated miR-10a as one of the most highly 
upregulated miRNAs in keratinocytes from AD patients (Rebane et al., 2014), 
we next focused on the studies on the function of miR-10a. We first confirmed 
that miR-10a was upregulated both in the non-lesional and lesional skin of AD 
patients compared with healthy controls (Figure 19A). Further, in situ hybridi-
zation analysis demonstrated that miR-10a was more highly expressed in the 
epidermis and its expression was stronger in AD patients compared with healthy 
controls (Figure 19B). To delineate the factors that might induce miR-10a 
expression in the skin, we stimulated the keratinocytes with various pro-inflam-
matory cytokines as well as TGF-β and retinoic acid, which have been shown to 
regulate miR-10a expression in T cells and dendritic cells (Takahashi et al., 
2012; Wu et al., 2015). As we could not detect cytokines to alter miR-10a levels 
in human primary keratinocytes (Study III, Figure S3. miR-10a-5p and miR-
146a expression in stimulated KCs.) and in situ hybridization results suggested 
miR-10a to be increased in the basal layer, we next tested whether miR-10a 
expression was associated with different stages of keratinocyte differentiation. 
To investigate that, we differentiated keratinocytes in the presence of high 
levels of Ca2+ or grew the cells in a 3D model and used KRT10 as a marker of 
keratinocyte differentiation. Figure 19C, 19D demonstrates that in later time 
points when KRT10 levels were increased, miR-10a levels were decreased in 
both models. To investigate whether growth factors supporting the keratinocyte 
proliferation might play a role in regulating miR-10a levels, we stimulated 
proliferating and 3D keratinocyte cultures with heparin‐binding EGF‐like 
growth factor (HB‐EGF). Indeed, miR-10a levels were increased in keratino-
cytes stimulated with HB-EGF compared with nonstimulated cells (Figure 19E, 
19F). Together, these results demonstrate that miR-10a expression is increased 
in AD, in proliferating keratinocytes and in response to HB‐EGF and is down-
regulated during differentiation of keratinocytes. 
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Figure 19. The expression of miR-10a in the skin and human primary keratino-
cytes. A,B) Relative expression of miR-10a by RT-qPCR (A) and in situ hybridization 
images (B) from nonlesional (AD NL) and lesional (AD L) skin of AD patients and 
healthy controls. (B) The expression of miR-10a appears in blue. Bar = 75 μm. The 
border between the epidermis and dermis is indicated with a dashed line. C-F) The 
expression analysis of miR-10a in monolayer and differentiation models. KRT10 was 
used as a differentiation marker. Data are shown as the mean ± SEM, n=4, student’s t-
test, *P < 0.05, **P < 0.01, #P < 0.05, ##P < 0.01. C) Keratinocytes were differentiated 
with high Ca2+ concentration. D, F) Reconstructed epidermis was used as a differen-
tiation model. Cells were seeded on the membrane at day 0, and arrow indicates the 
time when the apical media was removed. Trans‐epithelial electrical resistance (TER) 
was measured every 24 hours. In F), the in vitro reconstructed epidermis was stimulated 
with HB‐EGF or left nonstimulated (NS). E) The monolayer keratinocytes were 
stimulated with HB‐EGF or left nonstimulated (NS).  
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5.9. miR-10a modulates cell cycle and  
inhibits proliferation (Study II) 
To delineate the role of miR-10a in keratinocytes, we next analyzed a data set 
from the performed Illumina array analysis from the keratinocytes transfected 
miR‐10 and control mimics and stimulated with IL‐1β or left nonstimulated. 
317 upregulated and 522 downregulated genes were detected in cells transfected 
with control and stimulated with IL‐1β (differential P‐value < 0.05) compared 
to cells transfected with control and left nonstimulated confirming the effect of 
IL‐1β (Study III, Table S1. Top 200 genes induced by IL-1β). In the next step, 
we selected the top 200 genes downregulated by miR‐10a‐5p based on fold 
change in keratinocytes stimulated with IL‐1β, of which only 14 genes were 
differentially expressed according to the selected P‐value cut-off of 0.05. 
Considering that miRNA effects at a single gene level may be moderate, we 
included the full top 200 genes in the pathway analysis (Study III, Table S2. 
Top 200 genes downregulated by miR-10a-5p). The most prominent gene onto-
logy functional group that was affected by miR-10a was cell cycle regulation 
with 63 downregulated genes (P‐value of 7.0 × 10−18) (Study III, Table S3. 
miRNA-10a-5p downregulates genes associated with cell cycle regulation in 
KCs). Out of these 63 genes, 13 were putative direct targets of miR-10a (Figure 
20A) based on Targetscan (Agarwal et al., 2015; Lewis et al., 2005) prediction. 
As the array results revealed a strong potential miR-10a effect on cell prolife-
ration, we next did a set of experiments with keratinocytes transfected with 
miR‐10a or control mimic to assess the effect on proliferation. We first ana-
lyzed the cell cycle distribution based on DAPI, which revealed that in the cells 
transfected with miR-10, there were more cells in the G1/G0- and less in the S-
phase compared with the control (Figure 20B). Concordantly, in 5‐ethynyl‐2′‐
deoxyuridine (EdU) incorporation assay, fewer cells incorporated EdU and were 
in the S-phase when the cells were transfected with miR-10a (Figure 20C). 
Similarly, ATP-based proliferation assay revealed that increased levels of miR-
10a inhibited cell proliferation while LNA-inhibition of miR-10a led to in-
creased cell proliferation (Figure 20D). In line with this, the proliferation 
marker Ki-67 was downregulated in cells transfected with miR-10a in cells 
stimulated with IL-4, IL-17A, IL‐1β, or left nonstimulated (Figure 20E). On the 
other hand, when the endogenous levels of miR-10a were inhibited, an increase 
in proliferation-associated marker Ki-67 levels was detected only in the case of 
IL-17A stimulations (Figure 20F). The levels of Ki-67 were also increased in 
the lesional skin of AD patients compared with healthy controls (Figure 20G). 
These results together show that miR-10a has the capacity to inhibit keratino-
cyte proliferation.  
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Figure 20. miR-10a inhibits keratinocyte proliferation. A-F) Keratinocytes were 
transfected either with miR-10a (miR-10a-5p) or control or miR-10a inhibitor (LNA‐
miR‐10a) or control (LNA-control) for (A) 24 hours, (B, C, D) 48 hours or (E) 72 hours 
(A, C, E) and then stimulated with shown cytokines for additional 24 hours. A) Heat-
map of miR‐10a-influenced cell cycle associated predicted target genes. Log2 values of 
expression signals are mean-centered for each gene separately. The proposed direct 
targets of miR-10a are shown in bold. B) The cell cycle distribution based on the DAPI 
signal measured by flow cytometry. C) Cells were labeled with EdU for 2 hours before 
harvesting followed by measurement of DAPI and EdU signals by flow cytometry. D) 
CellTiter-Glo® Luminescent Cell Viability Assay. Nontrasnfected (NT) cells were 
included as an additional control. E, F) Relative Ki67 expression in transfected 
keratinocytes measured by RT-qPCR. G) Relative Ki67 expression in the nonlesional 
(AD NL) and lesional (AD L) skin of AD patients compared with the mean of healthy 
controls (Control) measured by RT-qPCR. B-G) Data are shown as the mean ± SEM, 
student’s t-test, *P < 0.05, **P < 0.01. 
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5.10. miR-10a has an anti-inflammatory effect in 
keratinocytes (Study II) 
miR-10a has been suggested to regulate the NF‐κB‐mediated inflammatory 
pathway by targeting the IκB/NF-κB regulators MAP3K7 or βTRC in arterial 
endothelial cells (Fang et al., 2010). To confirm the effect of miR-10a on genes 
associated NF‐κB pathway, we used the same experimental settings as for array 
analysis and analyzed mRNA levels of MAP3K7, CCL5, and IL-8 also by RT-
qPCR. We were able to confirm the downregulation of MAP3K7, a previously 
known direct target of miR-10a, in keratinocytes transfected with miR-10a 
(Figure 21A) as well as two NF‐κB‐dependent chemokines IL‐8 and CCL5 
were downregulated in keratinocytes transfected with miR-10a and stimulated 
with IL‐1β (Figure 21B). Based on our array data, cytokine signaling in the 
immune system (Figure 21C) appeared among other functional groups that were 
affected by miR-10a were in addition to cell cycle regulation cell adhesion, 
epithelium development, and abnormal skin morphology (Study III, Table S3. 
miRNA-10a-5p downregulates genes associated with cell cycle regulation in 
KCs). These results demonstrate that in addition to proliferation miR-10a is 
capable of suppressing the inflammatory responses of keratinocytes by inhibi-
ting the NF‐κB pathway leading to the reduced expression of chemokines IL‐8 
and CCL5. 
 
 
Figure 21. miR-10a has an anti-inflammatory effect in keratinocytes. Keratinocytes 
were transfected either with miR-10a (miR-10a-5p) or control for 24 hours and then 
stimulated with IL‐1β or left nonstimulated for additional 24 hours. A,B) Relative 
MAP3K7, CCL5, and IL-8 expression in transfected keratinocytes measured by RT-
qPCR. Data are shown as the mean ± SEM, student’s t-test, *P < 0.05, **P < 0.01. C) 
Heatmap of miR‐10a influenced genes from the cytokine signaling of the immune 
system pathway. Log2 values of expression signals are mean-centered for each gene 
separately. The proposed direct targets of miR-10a are shown in bold. 
 
 
  
74 
6. DISCUSSION 
6.1. The levels of miR-146a/b are increased in  
PV and regulated differently in keratinocytes and 
fibroblasts 
PV and AD are common chronic inflammatory skin diseases that have a high 
negative impact on patientsʼ quality of life (Werfel et al., 2016b). AD is as-
sociated with other atopic diseases like allergic rhinoconjunctivitis, allergic 
bronchial asthma, and food allergy and as the patients have a systemic Th2 type 
inflammation. In addition, AD is associated with ulcerative colitis (Werfel et al., 
2016a). PV on the other hand is associated with for example, metabolic syndro-
me and arthritis (Dainichi et al., 2018). However, in both diseases’ patients 
suffer from chronic cutaneous inflammation manifesting in the form of skin 
lesions. PV and AD are considered diseases that are mediated by specific types 
of T cells and the cytokines they produce, while the activation of other immune 
cells and their substantial migration to the skin also contributes to the patho-
genesis of both diseases (Guttman-Yassky & Krueger, 2017). The cytokines 
produced by immune cells activate various signaling pathways in keratinocytes 
leading to the changes seen in the epidermis, including epidermal hyperplasia, 
changes in keratinocyte differentiation, and parakeratosis, accounting for most 
of the overall PV and AD phenotypes (Guttman-Yassky et al., 2011). Therefore, 
the role of keratinocytes in the development of PV and AD cannot be over-
looked.  
In our study, we show the increased expression of miR-146a/b in the lesional 
skin of PV patients compared with healthy controls indicating that both miR-
146a and miR-146b play a role in the pathophysiology of PV. This is in line 
with previously published results where the increased expression of miR-146a/b 
in PV skin has been shown (Lovendorf et al., 2015; Sonkoly et al., 2007). In 
line with these results is the notion that miR-146a deficiency leads to earlier PV 
onset and more severe skin inflammation in the imiquimod-induced model of 
PV compared with wild type mice (Srivastava et al., 2017). The increased miR-
146a expression is not only characteristic of PV, it has been shown that miR-
146a is also upregulated in the non-lesional and lesional skin of AD patients 
(Rebane et al., 2014). Additionally, the same study showed that miR-146a-
deficient mice compared with wild type mice develop a stronger inflammation 
in a mouse model of AD (Rebane et al., 2014). This data demonstrates that 
miR-146a has an anti-inflammatory function in different chronic inflammatory 
skin diseases and not only PV. 
When comparing the expression of miR-146a and miR-146b, we could iden-
tify that miR-146a expression is higher in healthy skin, keratinocytes, and 
PBMCs. However, in fibroblasts, the expression level of these two miRNAs is 
relatively similar. This indicated that there is a need to study these miRNAs in 
detail as they might have different functions in keratinocytes and fibroblasts. 
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When studying the localization of miR-146a/b in the skin of PV patients, we 
could detect the increased expression of miR-146a in the epidermis of PV 
patients indicating that even though the expression of miR-146a was higher in 
cultured fibroblasts, in disease conditions, miR-146a is more strongly upregu-
lated in the keratinocytes. The expression of miR-146b was lower than miR-
146a expression in healthy skin. Interestingly, in PV patients, the expression of 
miR-146b was higher in some cases in the dermis compared with epidermis. 
The levels of miR-146b might be dependent on the type of immune cells 
infiltrating the dermis and stage of the disease. In line with this result, in the 
previous finding, miR-146b was only upregulated in the reticular dermis of PV 
lesional skin compared with PV non-lesional skin but not in the epidermis 
(Lovendorf et al., 2015). This indicates that in the case of PV, miR-146b might 
have a more important role in in the dermis. However, future studies are needed 
to clarify the role of miR-146b in the dermis and in association with PV. 
When fibroblasts and keratinocytes were stimulated with proinflammatory 
cytokines, the expression changes of miR-146a and miR-146b were observed to 
be different. miR-146a was upregulated in response to IL-17A, TNF-α, and IL-
1β in fibroblasts and keratinocytes. miR-146b was differently regulated in 
keratinocytes and fibroblasts and in case of keratinocyte differentiation. In 
monolayer keratinocytes, the expression of miR-146b was upregulated in 
response to IFN-γ and in the 3D model in response to IFN-γ and IL-22. In 
addition, in fibroblasts, miR-146b was upregulated in response to IL-1β. The 
lack of effect of IL-22 on miR-146b in monolayer keratinocytes can be 
explained by the fact that the expression of IL-22 receptor components IL-10RB 
and IL22RA1 is low in proliferating keratinocytes (Study I, Figure S2. Relative 
expression of marker genes and transepithelial resistance measurements of 
keratinocyte 3D cultures). The effect of IL-17A, TNF-α, and IL-1β on miR-
146a expression in keratinocytes was previously shown (Rebane et al., 2014). 
The mentioned cytokines will lead to the activation of NF-κB and MAPK path-
ways (Aggarwal, 2003; Li et al., 2019). Thus, our results confirm the previous 
studies demonstrating that miR-146a expression is induced trough the NF-kB 
pathway (Taganov et al., 2006). The effect of IFN-γ on miR-146b expression in 
keratinocytes is in line with the results that IFN-γ primarily activates the JAK/ 
STAT pathway (Boehm et al., 1997). Previously, miR-146b was shown to be 
induced by STAT3/6 (Paterson & Kriegel, 2017). The lack of effect of IFN-γ on 
miR-146b expression in fibroblasts, however, is interesting, as fibroblasts are 
known also to express the IFN-γ receptor components even in nonstimulated 
conditions (Takaoka et al., 2000). Together these data show the need to study 
these miRNAs in parallel both keratinocytes and fibroblasts as they are regu-
lated differently and might have specific functions in the dermis or epidermis 
and this could contribute to the pathogenesis of PV. 
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6.2. miR-146a/b suppress keratinocyte proliferation and 
may be the associated with PV 
To further clarify the role of miR-146a/b in keratinocytes, we performed a 
pathway analysis of a previously published array data (Rebane et al., 2014) 
revealing that in nonstimulated keratinocytes, cell proliferation-related genes 
were enriched among the set of 102 genes suppressed by miR-146a. Concor-
dantly, we observed that the overexpression of both miR-146a and miR-146b 
inhibited the proliferation of keratinocytes. It has been also shown that miR-
146a–deficient mice have increased epidermal hyperproliferation and that miR-
146-deficient mice have thicker epidermis compared with WT mice (Srivastava 
et al., 2017). These findings are in line with the effect of SNP rs2910164 in the 
coding region of the MIR146A. In the case of CG and GG alleles, there was an 
increased risk of PV and decreased levels of miR-146a that also leads to an 
increase of keratinocyte proliferation. The effect on keratinocyte proliferation 
was suggested to be mediated through the epidermal growth factor receptor 
(Zhang et al., 2014). We also performed genetic analysis using previous GWAS 
dataset. Interestingly, our in silico analysis showed evidence for the presence of 
two independent PV susceptibility loci in the MIR146A gene region rs2961920 
(odds ratio = 1.12, P = 0.0015) 853 bp upstream from miR-146a encoding 
sequence and rs184776122 (odds ratio = 0.80, P = 0.005) 37 kb downstream of 
the MIR146A gene. The marker rs2961920 was in perfect linkage disequilib-
rium (r2 = 1) with a functional polymorphism rs2910164 (Study I, Supple-
mentary Table S4. In silico association analysis of genetic markers of MIR146A 
and MIR146B) that was shown to be associated with PV in the Han Chinese 
population (Zhang et al., 2014) and Caucasians (Srivastava et al., 2017). miR-
146b has not been shown to be genetically associated with any skin diseases, 
however, there appears to be a link between miR-146b and gastric cancer: an 
SNP (rs1536309) 1066 bp upstream of the TTS of the miR-146b-5p precursor 
was found to be a prognostic factor for gastric cancer while individuals carrying 
the C allele were protected (Wang et al., 2018). Our results together suggest that 
both miR-146a/b have a role in regulating keratinocyte proliferation. 
To better understand the effect of miR-146a in PV, we also analyzed the 
expression of previously characterized inflammatory-related targets (IRKA1, 
CARD10, CCL5, IL-8) as well as less known targets SERPINB2 and FERMT1, 
in the skin of PV patients. Interestingly, we found that only the expression of 
CARD10 was downregulated in the lesional skin of PV patients while the other 
targets, IRAK1, CCL5, IL-8, SERPINB2, and FERMT1 were upregulated in the 
lesional skin of PV patients. FERMT1 was chosen from the array data, and 
because it was one of the genes implicated in the regulation of cell proliferation 
(Duperret & Ridky, 2014; Herz et al., 2006) and it was also a previously 
uncharacterized target for miR-146a. Similarly, SERPINB2 contained a miR-
146a/b putative binding site, as well as we expected it to have a functional 
influence on disease development because of its protease inhibitor activity 
(Kruithof et al., 1995). Also, the increased levels of SERPINB2 in PV (Lyons-
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Giordano et al., 1994) and other inflammatory or autoimmune diseases, such as 
asthma (Woodruff et al., 2007) and lupus erythematosus (Bechtel et al., 1996) 
had been shown earlier. Additionally, CCL5 was shown to be also upregulated 
in AD (Rebane et al., 2012), IRAK1 is upregulated in PV (Xia et al., 2012) and 
IL-8 is known to be upregulated in both AD and PV (Nedoszytko et al., 2014). 
Thus, these proteins regulate inflammatory responses in different conditions and 
are not only specific for PV. Apart from CARD10, miR-146a and its putative 
target genes were significantly upregulated in diseased conditions indicting to a 
strong activation of inflammatory signaling pathways, including the NF-κB and 
JAK/STAT pathway. These results demonstrate that the increased expression of 
miR-146a in the skin of PV patients is not sufficient to fully suppress the 
inflammation during the disease.  
Among miR-146a putative target genes, we considered FERMT1 important 
and performed several experiments to demonstrate miR-146a influence and to 
describe its function in association with PV. We show that the expression of 
FERMT1 in healthy skin was predominant in the basal layer. Interestingly, in 
the case of PV lesional skin, the expression of FERMT1 was detected also in 
other areas of the epidermis. This suggests that increased expression of 
FERMT1 in the skin is mostly due the changes in keratinocytes. We also 
showed that the expression of FERMT1 was suppressed by miR-146a on both 
mRNA and protein levels and confirmed that FERMT1 is a direct target of miR-
146a. Previously, it was described that FERMT1 localizes only to the dermal-
epidermal junction, especially in the basal keratinocyte layer (Herz et al., 2006; 
Siegel et al., 2003). Our result that FERMT1 is also expressed in the outer 
layers further indicates that it contributes to PV pathogenesis as it is known that 
in FERMT1 deficient skin, keratinocytes have reduced proliferation and in-
creased apoptosis (Herz et al., 2006; Siegel et al., 2003). Additionally, muta-
tions in the FERMT1 gene were shown to cause Kindler syndrome, a rare auto-
somal recessive disorder that is characterized by blistering, photosensitivity, and 
cutaneous atrophy (Jobard et al., 2003; Siegel et al., 2003). Our data together 
suggest that one of the functions of miR-146a in PV could be the suppression of 
keratinocyte hyperproliferation by downregulating FERMT1, a known positive 
regulator of keratinocyte proliferation. However, as miR-146a similar to other 
miRNAs has many target genes, the anti-proliferative effect of miR-146a is 
most probably mediated through multiple targets. The identification of addi-
tional miR-146a/b targets could further deepen our understanding of the role 
these miRNAs play in the development of inflammatory skin diseases. 
 
 
6.3. The function of SERPINB2 in keratinocytes and 
association with PV 
When we carried out the analyses and experiments with miR-146a/b targets in 
association with PV, we also performed linear regression analysis to search for 
an association of miR-146a/b and the target gene expression (Study I, Figure 
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S3. Correlation analysis miR-146a/b and target genes in the skin of PV pa-
tients). Interestingly, none of the target genes showed a significant positive or 
negative relationship with miR-146a levels in the skin of PV patient, except for 
SERPINB2 which relative expression was in a negative relationship with miR-
146a in the skin of PV patients. Going through the literature, we found that 
SERPINB2 a clade B or OVA‐like serine protease inhibitor subgroup member 
of the serpin superfamily, which is also known as PAI2 and functions in its 
extracellular form as an inhibitor of extracellular protease urokinase plasmino-
gen activator and tissue plasminogen activator (Kruithof et al., 1995). That 
function to convert plasminogen to plasmin which is a protease that is involved 
in the regulation of extracellular matrix degradation and cell migration (Schro-
der et al., 2014), and mediation of inflammation and tissue remodeling (Schu-
liga, 2015). Although shown to be overexpressed in PV and other diseased 
conditions like in the lesional epidermis of lupus erythematosus patients, 
(Bechtel et al., 1996; Gissler et al., 1993), the role of SERPINB2 in the skin is 
not so clear. Both extracellular and intracellular functions for SERPINB2 have 
been proposed in keratinocytes. In its extracellular form, SERPINB2 can inhibit 
keratinocyte proliferation by inhibition of urokinase plasminogen activator, 
which has a growth stimulatory effect (Hibino et al., 1999) and is proposed to 
protect the Stratum corneum in inflammatory conditions (Schroder et al., 2016). 
Its intracellular functions are less know and as it has been previously suggested 
that SERPINB2 is considered poorly secreted by keratinocytes (Jensen et al., 
1995) and therefore might have intracellular functions in the skin (Risse et al., 
2000) 
To detect the expression of SERPINB2 in the skin, we performed immuno-
fluorescence analysis and showed that SERPINB2 protein was detectable in the 
granular layer of the epidermis in healthy controls and PV patients’ non‐lesional 
skin. However, in the lesional skin of PV patients, it was visible that SER-
PINB2 expression was increased in the cornified layer and to a lesser extent all 
over the epidermis. As mentioned at the beginning of this chapter, in the case of 
SERPINB2, we detected a negative relationship between SERPINB2 mRNA 
and miR‐146a expression levels in the lesional skin of PV patients. As further 
evidence, ISH of miR-146a and immunofluorescence analysis of SERPINB2 
demonstrate that they both localize in the epidermis. However, although the 
3´UTR of SERPINB2 does contains a binding site for miR-146a, we were not 
able to confirm SERPINB2 as a direct target of miR-146a in keratinocytes. As 
siRNA silencing of CARD10 and IRAK1 led to the downregulation of 
SERPINB2 (Study II, Figure 3. The expression of SERPINB2 is suppressed by 
miR‐146a/b in human primary keratinocytes.), the effect of miR-146a on 
SERPINB2 expression may be mediated through NF‐κB members IRAK1 and 
CARD10. Additionally, regression analysis between PASI and SERPINB2 
mRNA expression in lesional skin samples from PV patients revealed a positive 
relationship between SERPINB2 mRNA levels and disease severity. This 
indicates that SERPINB2 might be potentially used as a biomarker of disease 
severity. Previously, it has been shown that SERPINB2 could be used as a 
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biomarker to help distinguish between different types of asthma and its severity 
(Baos et al., 2019; Baos et al., 2018). 
During analysis, which cytokines are capable of modulating SERPINB2 
expression in keratinocytes, we found TNF‐α and IFN‐γ as most prominent 
factors that enhanced both the cellular expression and amount of secreted 
SERPINB2. It should be noted, that the SERPINB2 levels in the supernatants 
were relatively high indicating that keratinocytes do secret SERPINB2 from the 
cells efficiently. Contradictory to our results, previous studies concerning skin 
had stated that SERPINB2 is poorly secreted by keratinocytes (Jensen et al., 
1995). Interestingly, more recent results have shown that SERPINB2 is secreted 
from the cells in response to inflammatory stimuli and is predominantly in its 
nonglycosylated 43kDa form as it released from endothelial cells (Boncela et 
al., 2013). Among cellular pathways important to the expression activation of 
SERPINB2, most probably the JAK/STAT signaling pathway contributes as 
IFN‐γ had a very strong positive effect on SERPINB2 levels in the keratino-
cytes. Additionally, it is known that the expression activation of SERPINB2 is 
also mediated through the activation of the NF‐κB signaling pathway (Mahony 
et al., 1999).  
To study SERPINB2 function in keratinocytes, we performed siRNA 
inhibition of SERPINB in keratinocytes, which interestingly led to the increased 
expression and secretion of IL-8 and CCL5. Thus, our results show that one 
function of SERPINB2 in the skin could be the regulation of cytokine levels of 
keratinocytes and through that influence the immune cell influx into the skin, 
thereby also participating in the regulation of PV related processes in the skin.  
 
 
6.4. Overexpression of single miR-146 family member 
suppresses and downregulation increases PV associated 
target genes in keratinocytes 
To assess whether miR-146b in addition to miR-146a has an influence on 
IRAK1, CARD10, CCL5, IL-8, FERMT1, and SERPINB2 expression in 
keratinocytes, we overexpressed both miRNAs in the human keratinocytes and 
observed similar effects, showing that miR-146a/b complement each other´s 
function in keratinocytes. Additionally, the inhibition of both miR-146a/b led to 
the increase in IRAK1, CARD10, CCL5, IL-8, FERMT1, and SERPINB2 con-
firming that miR-146 family members are crucial to avoid excessive inflam-
mation in keratinocytes. Interestingly, keratinocytes from mice deficient in 
miR-146a or miR-146b responded differently to pro-inflammatory cytokines. In 
case of nonstimulated, TNF‐α, or IL-17A stimulated cells, keratinocytes from 
miR-146a deficient mice had a stronger inflammatory response as seen by the 
increased expression of Card10 and Cxcl1 as well as a higher expression of 
Fermt1 compared with wild type mice. However, miR-146b deficient mice 
keratinocytes did not respond in a similar manner (Study I, Figure S10. 
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Deficiency of miR-146a or miR-146b results in the increased expression of the 
target genes). It is known, miR-146a expression in cells is induced by NF-κB 
pathway and miR-146b trough the STAT3/6 (Paterson & Kriegel, 2017). 
Altogether, this allows more robust repression of the NF-κB pathway as both 
miRNAs can suppress the targets to a similar extent. Interestingly, as miR-146a 
itself is upregulated by the NF-κB, it forms a negative feedback loop as after 
upregulation, it can suppress several members from the NF-κB pathway, which 
in keratinocytes include IRAK1, TRAF6, and CARD10 (Meisgen et al., 2014; 
Rebane et al., 2014). This leads to the decreased expression of several cytokines 
that are responsible for the increased expression of miR-146a itself, including 
TNF-α and IL-1β (Meisgen et al., 2014; Rebane et al., 2014). Additionally, 
miR-146b also inhibits the NF-κB pathway, therefore miR-146b supposedly 
influences miR-146a expression while there is apparently no direct effect of 
miR-146a on miR-146b expression. The different inflammatory responses in 
mice keratinocytes from miR-146a or miR-146b knock out mice show the need 
to distinguish miR-146a/b effects from each other as they could have indepen-
dent roles in the disease progression or development. More studies are needed 
to distinguish miR-146a/b roles in the skin and in association with PV. 
 
 
6.5. The levels of miR-10a are increased in AD patients and 
the regulation in keratinocytes 
AD is a chronic inflammatory skin disease associated with barrier defects, chan-
ges in keratinocyte proliferation, and immune dysregulation (Weidinger & No-
vak, 2016). Keratinocytes play a role in the development and maintaining in-
flammation in the skin as keratinocytes from AD patients produce higher levels 
of growth factors (GM-CSF), chemokines (CCL5), and cytokines (TNF-α, 
TSLP) as compared to normal keratinocytes (Soumelis et al., 2002). Before our 
work, a few studies had shown by microarray analysis or sequencing the expres-
sion changes of miR-10a in skin diseases. It has been shown that miR-10a is 
downregulated in PV (Joyce et al., 2011; Sonkoly et al., 2007), in systemic 
scleroderma (Zhou et al., 2017) and upregulated in keratinocytes from AD 
patients (Rebane et al., 2014). We confirmed the upregulation of miR-10a in the 
lesional and nonlesional skin of AD patients. Also, in situ hybridization showed 
that miR-10a is expressed in the epidermis of the skin and is increased in the 
lesional skin of AD patients.  
Our attempt to delineate the factors influencing the expression of miR-10a 
identified the growth factor HB-EGF capable of upregulating miR-10a expres-
sion in keratinocytes and additionally show that miR-10a expression is down-
regulated during keratinocyte differentiation. It has been previously shown that 
miR-10a expression is upregulated by growth-inducing factors TGF-β or reti-
noic acid (Takahashi et al., 2012) and downregulated by TNF and IFN-γ in 
human DCs (Wu et al., 2015). However, these growth-inducing factors and pro‐
inflammatory cytokines did not alter miR-10a expression in keratinocytes in our 
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case. Interestingly, HB-EGF is also known to be upregulated in the lesional skin 
of AD patients (Malaisse et al., 2014) and the excess release of HB-EGF as a 
result of inflammation and tissue stress may result in the pathological hyper-
plasia of cells (Takenobu et al., 2003). On the other hand, pro-HB-EGF has 
been shown to suppress cell proliferation (Iwamoto et al., 1999) and the expres-
sion of pro-HB-EGF is also increased in response to pro-inflammatory 
cytokines IL-1β and TNF-α (Yoshizumi et al., 1992).  
 
 
6.6. The function of miR-10a in keratinocytes 
As there was very little known about the functions of miR-10a in keratinocytes, 
we first carried out array analysis from the keratinocytes transfected with miR‐
10 mimics. Interestingly, the gene ontology functional group that was affected 
by miR-10a the most was cell cycle regulation. To delineate the role of miR-10a 
in regulating keratinocyte proliferation, we next performed a set of experiments 
where we overexpressed miR-10a in keratinocytes and measured the effect on 
cell cycle progression. A higher number of cells in the G1/G0-phase and less in 
the S-phase were detected indicating a slower cell cycle progression. Similarly, 
miR-10a inhibited the cell cycle progression of human cardiomyocyte pro-
genitor cells (Liang et al., 2014). Additionally, our results demonstrated that 
miR-10a downregulated the cell proliferation marker Ki-67 in keratinocytes 
even when the cells were stimulated with pro-inflammatory cytokines, while 
Ki-67 was upregulated in the lesional skin of AD patients. However, miR-10a's 
effect on cell proliferation appears to depend on the cell type or disease. For 
example, miR-10a has been shown to be upregulated and enhances cell migra-
tion, invasion, and growth in solid tumors like lung cancer (Yu et al., 2015) and 
thyroid carcinoma (Hudson et al., 2013). Concordantly, miR-10a has been 
shown to act as a tumor suppressor in the case of many cancers, including 
esophageal squamous cell carcinoma (Liu et al., 2018) and human cervical 
cancer (Zhai et al., 2017). 
In addition to cell cycle regulation, we confirmed the effect of miR-10a on 
cytokine signaling in the immune system in keratinocytes. We show that miR-
10a downregulates MAP3K7, IL-8, and CCL5 in keratinocytes. It is known that 
miR-10a also targets MAP3K7 in human aortic endothelial cells and thereby 
affects the NF‐κB signaling pathway (Fang et al., 2010). In human mesangial 
cells, it was shown that IL-8 is a direct target of miR‐10a (Tangtanatakul et al., 
2017). In conclusion, we show for the first time that miR-10a inhibits cell cycle 
progression in keratinocytes and additionally affects cytokine signaling by 
regulating IL-8 and CCL5 in keratinocytes. Thus, the role of miR-10a in AD 
might be to control of proliferation of keratinocytes and to dampen the exces-
sive inflammation. 
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6.7. General remarks and further studies 
miR-10a and miR-146a/b are not considered skin-specific miRNAs, however, 
they are still relatively highly expressed in the skin. Based on previous report, 
miR-10a has the highest expression in healthy skin followed by miR-146a and 
then miR-146b (Sahmatova et al., 2016). We identified miR-146a/b and miR-
10a to be expressed in the epidermis, and therefore, these three miRNAs can 
affect the development of PV and AD through their functions in keratinocytes. 
Interestingly, miR-146a/b and miR-10a seem to have similar functions in 
keratinocytes as they suppress inflammation and proliferation of the cells.  
The roles of miR-146a/b and miR-10a and targets are outlined in figure 22.  
 
 
 
Figure 22. The function of miR-146a/b and miR-10a in keratinocytes. miR-146a/b 
and miR-10a are transcribed by independent genes with different genomic locations. 
miR-146a expression is upregulated in response to NF-κB activation and miR-146b is 
regulated by STAT3/6 in response to specific cytokines (Taganov et al., 2006) (Paterson 
& Kriegel, 2017). miR-10a expression is regulated by keratinocyte differentiation and 
the growth factor HB-EGF. miR-146a/b and miR-10a suppress multiple targets in 
keratinocytes including members of the NF-κB pathways leading to the reduced activity 
of NF-κB, indicated by the blue arrow (Meisgen et al., 2014; Rebane et al., 2014). 
miRNA target genes are prone to be enriched in particular biological pathways in order 
to stabilize the gene regulatory networks (Bracken et al., 2016). miR-146a/b both target 
SERPINB2, IRAK1, CARD10, CCL5, IL-8 and FERMT1. miR-10a targets MAP3K7, 
CCL5, and IL-8 in keratinocytes. Together miR-146a/b and miR-10a inhibit inflam-
mation and proliferation of keratinocytes. Indicated by the blue arrow. 
83 
However, based on microarray analyses of the influenced genes, miR-146a/b 
have a significant effect on inflammation, and miR-10a influences more cell 
proliferation. It should be noted, that as our study was one of the first studies to 
show miR-10a function in the skin, further analysis of miR-10a function in AD 
mouse models would help to give deeper insight into the role of miR-10a in the 
development of AD. Still, based current knowledge that increased cell proli-
feration and skin inflammation are known features of both PV and AD 
(Boehncke & Schon, 2015; Weidinger & Novak, 2016), we conclude that miR-
146a/b and miR-10a affect essential disease-associated processes in the skin.  
As a result of the activation of the NF-κB pathway during inflammatory skin 
diseases, such as PV and AD, the expression of miRNAs themselves is changed. 
For example, miR-146a/b are highly upregulated in PV, however, miR-10a is 
downregulated (Sonkoly et al., 2007; Srivastava et al., 2019). In the case of AD, 
miR-10a and miR-146a are upregulated (Rebane et al., 2014; Sonkoly et al., 
2007). This indicates that the changes in miRNA expression levels can be 
disease-specific and could be used as biomarkers to distinguish between diffe-
rent diseases, as it has been also shown for PV and different types of skin cancer 
(Lovendorf et al., 2014; Neagu et al., 2020). Moreover, considering the results 
from the functional studies demonstrating that miR-10a and miR-146a inhibit 
inflammatory responses and keratinocyte proliferation, we propose that over-
expression of these miRNA may have therapeutic effect in case of inflammatory 
skin diseases. Indeed, it was shown that the subcutaneous pre-administration of 
cell penetrating peptide Pepfect6-miR-146a nanocomplexes alleviated the 
inflammation in a mouse model of irritant contact dermatitis indicated by the 
reduced expression of pro-inflammatory cytokines and attenuated ear-swelling 
(Urgard et al., 2016). In association with PV, it has been shown that the intra-
dermal administration of miR-146a mimics alleviated imiquimod-induced 
psoriasiform skin inflammation indicated by the reduced epidermal thickening, 
decreased numbers of proliferating keratinocytes, and infiltrating neutrophils 
(Srivastava et al., 2017). Future studies will bring additional knowledge on the 
field of miRNA studies and eventually may lead to the development of miRNA-
based therapeutics for various conditions, including chronic inflammatory 
diseases. 
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7. CONCLUSIONS 
1. The expression of miR-146a/b and their target genes, IRAK1, CCL5, IL-8, 
and FERMT1 was shown to be increased while CARD10 was decreased in 
the lesional skin of PV patients compared with healthy controls. miR-146a/b 
suppress the proliferation of keratinocytes most probably through multiple 
targets, among which we characterize novel direct target FERMT1. Similarly 
to miR-146a, miR-146b suppresses the inflammation in keratinocytes by 
downregulating inflammation-related targets IRAK1, CARD10, CCL5, and 
IL-8.  
2. The increased expression of SERPINB2 in the lesional and non-lesional skin 
of PV patients was shown at mRNA and protein levels. A positive relation-
ship between PV severity and relative SERPINB2 mRNA expression and a 
negative relationship between the relative level of miR-146a and SERPINB2 
mRNA were detected. In keratinocytes stimulated with IFN‐γ and TNF‐α, 
SERPINB2 mRNA, as well as intracellular and secreted protein levels, were 
significantly increased. miR-146a was shown to suppress SERPINB2 mRNA 
and protein levels indirectly. The inhibition of SERPINB2 increased the 
expression and protein levels of CCL5 and IL-8, thus indicating that 
although miR-146a has the capacity to suppress SERPINB2, they both pos-
sess anti-inflammatory influence and may act synergistically. 
3. The increased expression of miR-10a in the lesional skin of AD patients was 
demonstrated. By ISH, miR-10a was shown to localize to the epidermis and 
there was increased expression of miR-10a in AD lesional skin. The expres-
sion of miR-10a was shown to be dependent on keratinocyte differentiation 
and was upregulated by HB-EGF. The array analysis, cell cycle measure-
ments, and proliferation assays using miR-10a-transfected keratinocytes 
demonstrated that miR-10a hinders the progression of the cell cycle and 
thereby inhibits keratinocyte proliferation. Additionally, miR-10a modera-
tely inhibits inflammation-associated genes in keratinocytes. 
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8. SUMMARY IN ESTONIAN 
MikroRNA-d keratinotsüütide rakulise vastuse  
reguleerimisel naastulise psoriaasi ja atoopilise  
dermatiidi korral 
Nahk on meie organismi suurim organ, mille põhifunktsiooniks on kaitsta meid 
väliskeskkonna mõjude, sealhulgas erinevate patogeenide eest. Oma funktsioo-
nide täideviimiseks on nahal kolm kihti: epidermis, dermis ja hüpodermis. Epi-
dermis jaguneb omakorda neljaks: basaalkiht, ogakiht, sõmerkoht ja sarvkiht. 
Keratinotsüüdid on epidermise peamine raku tüüp ja moodustavad 90% kõigist 
epidermise rakkudest. Jagunemisvõimelised keratinotsüüdid paiknevad epider-
mise basaalkihis ning edasisel diferentseerumisel migreeruvad nad välimistesse 
kihtidesse moodustades epidermise pindmised kihid. Keratinotsüütide prolife-
ratsiooni kontroll on oluline epidermise struktuuri ja funktsiooni säilitamiseks. 
On teada, et suurem osa basaalkihi keratinotsüüte on tegelikult G0/G1 faasis ja 
ei jagune. Keratinotsüütide hüperproliferatsioon on paljude krooniliste põletiku-
liste nahahaiguste üheks põhiliseks tunnuseks. Lisaks oma põhifunktsioonile 
olla füüsiliseks barjääriks organismi ja keskkonna vahel, vahendavad keratino-
tsüüdid signaale keskkonnast imuunrakkudele ning seetõttu reguleerivad nii 
kaasasündinud kui ka omandatud immuunvastuseid. Häired keratinotsüütide 
signaliseerimises võivad olla seotud või olla üheks põhjuseks erinevate naha-
haiguste, näiteks atoopiline dermatiidi ja psoriaasi puhul.  
Psoriaas ja atoopiline dermatiit on kroonilised põletikulised nahahaigused 
ning on suhteliselt sagedased üldpopulatsioonis. Psoriaasi sagedus Euroopas ja 
Ameerika Ühendriikides on keskmiselt 2–3%. Kõige levinum psoriaasi vorm on 
naastuline psoriaas (psoriaasis vulgaris), mis moodustab ligi 90% kõigist juh-
tudest. Naastulist psoriaasi iseloomustavad sümmeetriliselt paiknevad puneta-
vad infiltreeritud ja ketendavad naastud juustega kaetud peanahal ja jäsemete 
sirutuspindadel. Samas võib löövet olla ulatuslikult üle kogu keha ja haigel võib 
kujuneda erütrodermia, kus lööbest on haaratud rohkem kui 80% kehapinnast. 
Lisaks kvõib kaasneda nahalööbele psoriaatiline küünte- ja liigeskahjustus. 
Atoopilise dermatiidi sagedus on täiskasvanutel 2–5% ja lastel isegi kuni 20%. 
Atoopilist dermatiiti iseloomustab piinavalt sügelevate, erütematoossete, lihhe-
niseeritud kollete esinemine näol ja jäsemete painutuspindadel, samas analoog-
selt psoriaasiga patsientidele võib lööve esineda generaliseeritult üle kogu keha.  
Tüüpiliselt on ka kahjustatud patsientide nahabarjäär. Mõlemal haigusel on 
geneetiline eelsoodumus, kuid ka keskkonna faktorid mängivad rolli haiguste 
avaldumises. Samuti mängivad mõlema haiguse patogeneesis olulist rolli kerati-
notsüüdid, mis mõjutavad erinevaid haiguse faase läbi tsütokiinide tootmise ja 
oma pinnaretseptorite ekspressiooni. Selle tulemusena suureneb immuun-
rakkude liikumine nahka ning kujuneb psoriaasile või atoopilisele dermatiidile 
vastav iseloomulik immuunkeskkond nahas. 
miRNA-d on lühikesed üheahelalised mittekodeerivad RNA molekulid, mis 
reguleerivad geeniekspressiooni transkriptsiooni järgselt. miR-146a ja miR-
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146b (miR-146a/b) kuuluvad miR-146 perekonda ja kuna nad erinevad 3ʼ alas 
ainult kahe nukleotiidi poolest, siis arvatakse, et nad inhibeerivad samu geene. 
miR-146a/b funktsiooni on eelnevalt uuritud nahas seoses põletikuliste protses-
sidega ja on näidatud, et nad on võimelised inhibeerima mitmeid NF-κB 
signaaliraja liikmed. miR-10a kuulub miR-10 perekonda ning selle funktsioon 
on nahas suhteliselt tundmatu. miR-10a funktsioone on enim uuritud seoses 
organismide arenguprotsesside ja rakkude diferentseerumisega, eelkõige seoses 
erinevate vähkkasvajatega. Antud töös uurisime miR-146a/b ja miR-10a 
ekspressiooni nahas ja nende funktsioone keratinotsüütides seoses vastavalt 
psoriaasiga ja atoopilise dermatiidiga.  
 
Uurimistöö eesmärgid: 
Käesoleva uuringu eesmärkideks oli iseloomustada miR-146a/b ja miR-10a 
rolle keratinotsüütides ning seda, kuidas need aitavad kaasa psoriaasi ja atoopi-
lise dermatiidi arengule. 
Uuringu täpsemateks eesmärkideks olid: 
–  Teha kindlaks, kas miR-146a/b ja sihtgeenide ekspressioon on muutunud 
naastulise psoriaasi patsientide nahas võrreldes kontrollproovidega ning ana-
lüüsida kas ja kuidas miR-146a/b mõjutavad psoriaasiga seotud protsesse, 
sealhulgas proliferatsiooni ja rakulisi vastuseid, keratinotsüütides. 
–  Selgitada välja oletatava miR-146a/b sihtgeeni, SERPINB2, ekspressiooni 
regulatsiooni mõjutavad faktorid ja tema funktsioonid keratinotsüütides 
seoses psoriaasiga. 
–  Kirjeldada miR-10a ekspressiooni atoopilise dermatiidi haigete nahas ning 
uurida miR-10a ekspressiooni regulatsiooni ja funktsioone keratinotsüütides 
ja seoses atoopilises dermatiidiga. 
 
Materjal ja meetodid: 
Antud töös kasutati naha proove, mis olid kogutud Tartu Ülikooli Nahahaiguste 
kliinikus ja Kieli Ülikooli haiglas Saksamaal. Kõiki uuringus teostatud katsed, 
kus kasutati patsientidelt ja tervetelt vabatahtlikelt pärinevaid materjale, on 
heaks kiidetud vastavate asutuste eetikakomiteede poolt. Samuti informeeriti 
kõiki doonoreid eelnevalt katse eesmärkidest ja kõigilt koguti allkirjastatud 
informeeritud kirjalikud nõusolekuvormid. Kogutud nahaproovid külmutati ja 
hoiustati RNA eraldamiseni või koelõikude valmistamiseni -80º C juures. 
Uuringutes I ja II värvati kokku 27 naastulise psoriaasi patsienti ja 27 kontrolli 
RT-qPCR, korrelatsiooni analüüside, in situ hübridisatsiooni ja immuunfluorest-
sents analüüside jaoks. Patsientide vanus varieerus 21st 65 aastani (keskmine 
48); 27st patsendist 9 olid naised ja 18 mehed. PASI väärtus varieerus 7–33ni. 
Uuringus III kasutati 10 atoopilise dermatiidi patsiendi naha biopsiat. Atooplise 
dermatiidi patsientidest 5 olid naised ja 5 mehed vanuses 22 kuni 58. Lisaks 
kasutati 15 sobiva soo ja vanusega kontrollindiviidi (7 meest ja 8 naist vanuses 
20 kuni 59). Antud proovides analüüsiti miR-146a/b ja miR-10a ning CARD10, 
IRAK1, CCL5, IL-8, FERMT1, SERPINB2, Ki67 ja MAP3K7 mRNA ja/või 
valgu ekspressiooni. 
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Selgitamaks välja kas miR-146a/b võib olla seotud psoriaasi patogeneesiga, 
kasutati rakukultuuride mudeleid. Kõigepealt stimuleeriti naha primaarseid 
keratinotsüüte ning fibroblaste psoriaasiseoseliste tsütokiinidega (IFN-γ, TNF-
α, IL-1β, IL-17A ja IL-22) ning analüüsiti miR-146a/b ekspressiooni. miR-
146a/b mõju proliferatsioonile kindlaks tegemiseks transfekteeriti miRNA-de 
prekursorid või inhibiitorid keratinotsüütidesse ning hinnati mõju proliferat-
sioonile ja eluvõimele. Kasutades proliferatsiooni hindamiseks radioaktiivselt 
märgistatud tümidiini ning eluvõime hindamiseks CellTiter-Glo® Lumine- 
scent Cell Viability analüüsikomplekti, mis kvantifitseerib rakkudes olevat  
ATP-d. Samuti analüüsiti geenide CARD10, IRAK1, CCL5, IL-8, FERMT1, 
SERPINB2 ekspressiooni RT-qPCR-ga. 
miR-146a mõju uurimiseks FERMT1 mRNA ja valgu ekspressioonile, trans-
fekteeriti keratinotsüüdid miR-146a prekursoriga ja analüüsiti FERMT1 taset 
nii mRNA tasemel kasutade RT-qPCRi, kui ka valgu tasemel kasutades western 
blotti. Tuvastamaks, kas FERMT1 on miR-146a otsene sihtmärk, kloneeriti 
FERMT1 3’UTR fragmendid, mis sisaldasid kas miR-146a või muteeritud miR-
146a seondumissaiti, pmirGLO Dual-Luciferase ekspressiooni vektorisse ning 
mõõdeti kasutades Dual-Luciferase® Reporter Assay süsteemi firefly ja renilla 
lutsiferaasi aktiivsust. 
SERPINB2 funktsiooni uurimiseks stimuleeriti keratinotsüüte põletikku 
soodustavate tsütokiinidega ja analüüsiti SERPINB2 taset rakkudes mRNA 
tasemel kasutades RT-qPCR-i ja valgu tasemel kasutades immuunfluorestsents-
analüüsi ja ELISA-t. Lisaks pärsiti endogeense SERPINB2 avaldumist siRNA-
de abil, misjärel analüüsiti IL-8 ja CCL5 mRNA ja valgu tasemeid kasutades 
esimesel juhul RT-qPCR-i ja teisel juhul ELISA meetodit. 
miR-10a ekspressiooni regulatsiooni uurimiseks kasvatati inimese primaar-
seid keratinotsüüte nii 2D kui ka 3D kultuuris ning stimuleeriti HB-EGF-iga, et 
hinnata keratinotsüütide diferentseerumise mõju miR-10a ekspressioonile. miR-
10a taset analüüsiti RT-qPCR-ga. miR-10a funktsioonide kindlaks tegemiseks 
transfekteeriti keratinotsüütidesse miR-10a prekursorid ja hinnati mõju trans-
kriptoomile mRNA kiibil. Järgmisena transfekteeriti keratinotsüütidesse miR-
10a prekursorid ja inhibiitorid ning analüüsiti mõju rakkude proliferatsioonile 
kasutades läbivoolutsütomeetriat ning hinnati proliferatsiooni markergeeni Ki67 
ekspressiooni RT-qPCR-i abil. Lisaks analüüsiti geenide CCL5, IL-8 ja 
MAP3K7 ekspressiooni RT-qPCR-iga. 
 
Uurimistöö peamised tulemused ja järeldused: 
Antud töös tegime kindlaks, et miR-146a/b ja nende sihtmärkgeenide IRAK1, 
CCL5, IL-8 ja FERMT1 ekspressioon oli kõrgem, samal ajal kui CARD10 
ekspressioon oli madalam psoriaasi patsientide lööbelises nahas. Samuti näita-
sime, et miR-146a/b ekspressioon suureneb keratinotsüütides ja fibroblastides 
vastusena põletikulistele tsütokiinidele. Leidisime, et miR-146a/b surub alla 
keratinotsüütide proliferatsiooni tõenäoliselt läbi mitme sihtgeeni, mille hulgas 
iseloomustasime uue miR-146a otsese sihtgeeni FERMT1. Sarnaselt miR-146a-
le pärsib miR-146b ka keratinotsüütides põletikuliste protsesside ning prolife-
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ratsiooniga seotud sihtgeenide IRAK1, CARD10, CCL5, IL-8, SERPINB2 ja 
FERMT1 avaldumist, kusjuures miR-146a/b endogeense taseme allasurumisel 
oli samade sihtgeenide tase kõrgem.  
Teiseks uurisime antud töös SERPINB2 funktsioone keratinotsüütides seoses 
psoriaasiga. Tuvastasime SERPINB2 suurenenud ekspressiooni psoriaasi pat-
sientide nahas mRNA ja valgu tasemel, avastasime positiivne seose psoriaasi 
raskusastme ja SERPINB2 mRNA suhtelise ekspressiooni vahel ning negatiivse 
seose miR-146a ja SERPINB2 mRNA suhteliste tasemte vahel. Leidsime, et 
IFN-γ ja TNF-α-ga stimuleeritud keratinotsüütides tõusis märkimisväärselt 
SERPINB2 mRNA ning ka rakusisese ja sekreteeritud valgu tase ning et miR-
146a vähendab nendes tingimustes SERPINB2 avaldumist. Lisaks näitasime, et 
SERPINB2 endogeense taseme vähendamine suurendas CCL5 ja IL-8 mRNA 
ekspressiooni ja valgu taset.  
Töö viimases osas tuvastasime miR-10a suurenenud ekspressiooni atoopilise 
dermatiidi patsientide nahas ning näitasime, et miR-10a lokaliseerub eelkõige 
epidermises. Leidsime, et miR-10a ekspressioon väheneb keratinotsüütide dife-
rentseerumisel ja HB-EGF stimuleerib miR-10a ekspressiooni nii proliferee-
ruvates kui ka diferentseeruvates keratinotsüütides. Lisaks näitasime, et miR-
10a on võimeline keratinotsüütides takistama rakutsükli kulgu ja pärsib seeläbi 
keratinotsüütide proliferatsiooni. miR-10a inhibeeris ka mõõdukalt põletikuliste 
protsessidega seotud geene MAP3K7, IL-8 ja CCL5 keratinotsüütide.  
Kokkuvõttes näitavad meie tulemused, et miR-146a/b on võimelised suruma 
alla proliferatsiooni ja põletikulisi protsesse keratinotsüütides, kuid miR-146a/b 
kõrgem ekspressioon psoriaasihaigete nahas ei ole suuteline ära hoidma  
sihtmärkgeenide ekspressiooni tõusu ja haigusenähte. Lisaks näitasime, et 
SERPINB2 omab võimet pärssida põletikulisi protsess keratinotsüütides. Samu-
ti viitavad meie tulemused, et kuigi miR-146a inhibeerib SERPINB2 ekspres-
siooni on neil mõlemal põletikuvastane mõju ja nad võivad toimida keratino-
tsüütides ja psoriaasi haigete nahas sünergiliselt. Oma töö kolmandas artiklis 
leidsime, et miR-10a tase on atoopilises dermatiidis tõusnud ja mõjutab haigus-
seoselisi protsesse, nagu seda on proliferatsioon ja põletik, kuid tema taseme 
tõus atoopilise dermatiidi patsientide nahas ei ole piisav, et ära hoida atoopilise 
dermatiidi teket. Meie tulemused viitavad, et miR-146a/b ja miR-10a lokaalne 
manustamine võiks olla üks potentsiaalseid terapeutilisi võimalusi põletikuliste 
nahahaiguste korral.  
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